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Summary 
The von Hippel-Lindau protein (pVHL) is a tumor suppressor with a 
well-known function as key component of the pVHL E3 ubiquitin ligase 
complex, mediating degradation of hypoxia-inducible factor α (HIF-α) proteins. 
The main objective of our study is to gain new insight into the function of 
pVHL through exploring its interacting and cooperating proteins. In the first 
part of this project, we have identified and investigated novel pVHL 
interacting proteins. A key metabolic enzyme, fatty acid synthase (FASN) was 
identified through affinity purification of protein complexes and mass 
spectrometry analysis. Further functional studies revealed that FASN could 
regulate HIF-α protein levels via pVHL. The HIF-α induction by FASN in 
adipocyte differentiation process as well as sterol effects on HIF-α indicated 
the physiological importance of this regulation. The positive correlation of 
expression levels between FASN and HIF-α target genes was observed in 
human prostate cancer patient specimen, which may indicate a clinical 
significance. In the second part of the project, we have investigated the 
potential tumor suppressor function of a histone H3K27 demethylase, 
Ubiquitously Transcribed X Chromosome Tetratricopeptide Repeat Protein 
(UTX), which has been reported to be co-mutated with VHL in human clear 
cell renal cell carcinoma (ccRCC). We showed that UTX was important to 
suppress anchorage-independent cell growth of transformed mouse 
embryonic fibroblast cells and HeLa cells. Regarding the underlying 
XIV 
 
mechanism, microarray gene expression profiling analysis suggested some 
signaling pathways such as mTOR pathway might be responsible. Moreover, 
we looked into the question whether the catalytic activity of UTX or its 
interaction with the MLL2 complex, a H3K4 methyltransferase, were 
important for the potential tumor suppressing activity. In summary, our work 
may provide a deeper understanding of the function of pVHL with respect to 
tumorigenesis.
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Chapter 1 Introduction 
Overview 
Understanding of the molecular basis of cancer development can always 
provide solid background information for cancer prognosis or cancer therapy. 
In order to explore the molecular basis of cancer development, it is important 
to understand the essential processes determining the fate of cancer cells, 
such as transcriptional regulation, ubiquitination, epigenetic modification and 
metabolism. Therefore, it is critical to study the function of some specific 
molecules that play crucial roles in these processes.  
 
 
  
2 
 
1.1 Ubiquitination regulating biological processes and the E3 
ligase component pVHL 
 
1.1.1 Ubiquitination regulating biological processes 
The ubiquitin-proteasome system is a post-translational mode of regulation, 
known to eliminate damaged proteins, or degrade functional proteins which 
need to be tightly controlled. Since most of these targeted proteins are 
generally key elements of pathways controlling fundamental biological 
processes such as cell cycle, transcription, signal transduction and 
metabolism (Ciechanover 2005), it is important to thoroughly investigate the 
function of molecules involved in specific ubiquitin-proteasome system 
processes.  
 
The ubiquitin-proteasome system regulates the degradation of target 
substrate proteins by multiple steps including recognition, ubiquitination and 
proteasomal degradation of substrates. Firstly, ubiquitin activating enzyme E1 
induces ATP-dependent activation of ubiquitin molecules by forming a 
thiol-ester bond; secondly, the ubiquitin conjugating enzyme E2 takes over 
the activated ubiquitin molecules from E1 by a trans-esterification reaction; 
thirdly, the E3 ubiquitin ligase transfers the ubiquitin molecules from E2 to 
the target substrate protein by forming an isopeptide bond. This modification 
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can be either single ubiquitination or polyubiquitination. Polyubiquitination is 
the formation of a chain-like structure by multiple ubiquitin molecules 
(Ciechanover 1994). Finally, the polyubiquitinated substrate protein is 
recognized by the 26S proteasome and subjected to degradation into short 
peptides. Regarding this proteasomal degradation step, a minimum of four 
ubiquitin molecules on the substrate protein are required for recognition 
(Hicke 2001). The 26S proteasome is a large protein complex composed of 
two 19S regulatory particles responsible for recognition, and one 20S 
proteasome responsible for degradation (Thrower, Hoffman et al. 2000; 
Adams 2003).  
 
Another important mechanism is the reversibility of the ubiquitination 
process. Deubiquitinating enzymes can remove ubiquitin from target 
substrate proteins thus preventing the degradation (Wilkinson 2000). This 
reversible process of ubiquitination and deubiquitination offers the possibility 
to regulate the target substrate proteins in a more controlled way. 
 
Compared to other elements of the above-mentioned ubiquitin-proteasome 
system, E3 ubiquitin ligases are the most varied, with hundreds of E3 ligases 
identified so far (Pickart 2001). The diversity of E3 ubiquitin ligases allows 
their recognition of various target proteins regulating different downstream 
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pathways. Thus, dysfunction of the E3 ligase can lead to aberrant downstream 
biological processes. 
 
E3 ligases are classified into two major categories according to their 
protein-binding domains: RING finger E3 ligases and HECT domain E3 ligases 
(Pickart 2001). We have focused on a protein belonging to the former 
category: a complex containing the von Hippel-Lindau protein (pVHL), as well 
as Ring-Box 1 (Rbx1), Elongin C, Elongin B and cullin 2 (CUL2) (Duan, Pause et 
al. 1995; Kibel, Iliopoulos et al. 1995; Pause, Lee et al. 1997). The detailed 
function of this particular E3 ligase will be reviewed in the following 
paragraphs. 
 
1.1.2 The E3 ligase pVHL 
 VHL mutation in ccRCC 
The well-understood clinical relevance of pVHL function is closely related to 
clear cell renal cell carcinoma (ccRCC). ccRCC is a major type of kidney cancer 
responsible for up to 90 % of the adulthood renal cell carcinoma cases 
(Nickerson, Jaeger et al. 2008; Moore, Nickerson et al. 2011). It is also known 
as the most malignant disease among genitourinary cancers. Regarding the 
molecular pathogenesis of this disease, the tumor suppressor gene VHL was 
first discovered to be responsible for the hereditary ccRCC, through linkage 
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analyses and molecular cloning. Later this gene was mapped to chromosome 
3p25-26. After the VHL gene was identified, it was also found to be mainly 
involved in the development of sporadic ccRCC (Zbar, Brauch et al. 1987; Latif, 
Tory et al. 1993). Following the classic Knudson “two-hit” theory of 
carcinogenesis (Knudson and Strong 1972), patients firstly inherit (hereditary 
cases) or spontaneously get (sporadic cases) a single faulty copy of VHL. 
Therefore, if spontaneous inactivation happens to the second wild-type VHL 
allele, the disease would be triggered to develop.  
 
The reported prevalence of VHL defects in ccRCC demonstrated that VHL 
mutations are important in ccRCC development. Almost all the recorded 
hereditary ccRCC and approximately 50 % of the sporadic ccRCC have biallelic 
VHL defects. In approximately 20 % of the sporadic ccRCC, a hypermethylated 
VHL promoter was detected (Kim and Kaelin 2004). However, according to 
these studies, in 10 %-20 % of these sporadic ccRCC cases there was no VHL 
alteration detected. This fact indicates that there are still other gene 
mutations responsible for ccRCC development. Recent large scale sequencing 
projects elucidated some novel and potentially responsible genes such as 
SETD2, PBRM1, UTX, JARID1C and genes within the PTEN-mTOR pathway, etc. 
(Dalgliesh, Furge et al. 2010; Varela, Tarpey et al. 2011; Sato, Yoshizato et al. 
2013; Scelo, Riazalhosseini et al. 2014) Interestingly, multiple scattered or 
metastasized ccRCC lesions in the kidney carry a different set of mutations 
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(Gerlinger, Rowan et al. 2012; Gerlinger, Horswell et al. 2014; Ricketts and 
Linehan 2014), whereas all the primary and metastasized lesions have a VHL 
mutation. This suggests that VHL mutation in an early stage is prerequisite for 
further gain of mutation and malignancy. In this sense, a recent report is quite 
intriguing, showing that combinational mutations of Vhl and p53 can cause 
renal cysts and tumors in mouse, providing a good example of combinational 
effects due to multiple mutations in tumorigenesis (Albers, Rajski et al. 2013).  
 
 General function of pVHL 
The VHL gene encodes a single mRNA that gives rise to two protein products: 
the full-length isoform pVHL25 and the truncated isoform pVHL19, which is 
generated due to an internal initiation of translation (Iliopoulos, Ohh et al. 
1998). So far no clear functional distinction is known between the two 
protein products and both of them must be dysfunctional for tumors to arise 
(Barry and Krek 2004). In this work the full-length isoform pVHL25 was used 
and it is referred to as pVHL in this thesis.  
 
The 25kDa pVHL protein has been reported to have multiple functions. One 
of the well-known functions is its E3 ubiquitin ligase activity as mentioned 
above. Together with Elongin C, Elongin B, CUL2 and Rbx1 (Duan, Pause et al. 
1995; Kibel, Iliopoulos et al. 1995; Pause, Lee et al. 1997)), this 
pVHL-containing E3 ubiquitin ligase complex targets the hypoxia-inducible 
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factor alpha (HIF-α) for ubiquitination and degradation. In normoxia, HIF-α 
protein is hydroxylated by prolylhydroxylases (PHDs) on specific proline 
residues. Then HIF-α is recognized by pVHL, polyubiquitinated by this E3 
ligase complex and degraded by the proteasome complex. In hypoxia or in 
presence of non-functional pVHL proteins, HIF-α is not recruited to the E3 
ligase complex, and the subsequent ubiquitination process mediated by pVHL 
is thus impaired. Under this condition, HIF-α is allowed to accumulate in 
nucleus, dimerize with ARNT (HIF1β), and bind to the hypoxia response 
elements (HREs) on target promoters to constitutively activate hypoxia 
inducible genes (Figure 1-1). These hypoxia inducible genes are highly 
involved in regulation of e.g. angiogenesis, metabolism, cell growth, and cell 
differentiation. The constitutive activation of target genes in this process 
eventually leads to the formation of pVHL-associated cancers (Kim and Kaelin 
2004). Apart from this pathway, a number of unknown proteins interacting or 
cooperating with pVHL may also be involved in tumorigenesis. However, they 
have not yet been identified or well characterized. It is also possible that 
co-mutations of VHL and a set of these genes can exert a decisive role by 
combinational (i.e. synergistic, compensatory or distinct) effects during the 
tumor formation process. 
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 HIF-α-independent function of pVHL  
In addition to HIF-α and pVHL E3 ligase components including Elongin C, 
Elongin B, CUL2 and Rbx1, there are other pVHL interacting proteins identified 
such as the RNA polymerase II (Na, Duan et al. 2003) and KLF4 (Gamper, Qiao 
et al. 2012) etc.. Independent from its E3 ligase function, pVHL has also been 
shown to regulate microtubule stability (Thoma, Toso et al. 2009). However, 
Figure 1-1 The pVHL-containing E3 ubiquitin ligase complex targets HIF-α 
for ubiquitination and degradation. In normoxia, HIF-1α and HIF-2α 
proteins are hydroxylated by PHDs and recognized by pVHL, 
polyubiquitinated and degraded by the proteasome complex. In hypoxia or 
in presence of non-functional pVHL proteins, HIF-1α and HIF-2α proteins 
are allowed to accumulate in nucleus, dimerize with ARNT (HIF1β), and 
bind to the HREs on target promoters to constitutively activate hypoxia 
inducible genes. 
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none of these published HIF-α-independent functions of pVHL were shown to 
have a clinical relevance to pVHL-associated tumorigenesis so far.  
 
 Phenotypes of Vhl knockout mice  
In order to mimic the human disease model, researchers such as Haase have 
been establishing and studying the Vhl knockout mouse models for 
years(Gnarra, Ward et al. 1997; Haase, Glickman et al. 2001). However, the 
results from mouse model studies are quite discrepant from real human 
disease situation. Importantly, no malignant tumors arise in the Vhl knockout 
mouse model. The discrepancy between the mouse models and the human 
disease phenotypes suggests that an unknown molecular mechanism, in 
addition to pVHL loss of function, might be involved in the ccRCC 
development.  
 
Constitutive Vhl knockout mice 
Homozygous disruption of the Vhl gene in mice results in embryonic lethality 
during mid-gestation, at E11.5-12.5. Placentae from Vhl-deficient embryos fail 
to develop syncytiotrophoblast and labyrinth properly, and show sign of 
hemorrhage (Gnarra, Ward et al. 1997), suggesting that abnormal placental 
vascularization leads to embryonic lethality. Since one of HIF-α’s downstream 
target genes VEGF is responsible to trigger angiogenesis, this embryonic 
lethality may be caused by dysregulation of pVHL-HIF-α-VEGF pathway in 
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early embryonic development (Haase, Glickman et al. 2001). It is not 
surprising to observe embryonic lethality in Vhl knockout mice. It is well 
known that genes important for tumorigenesis are often crucial for 
embryogenesis as well, since both events are closely related to the control of 
cell proliferation and differentiation. 
 
Conditional Vhl knockout mice 
Haase and colleagues performed tissue-specific inactivation of the Vhl gene in 
adult mice using conditional gene targeting technique based on 
Cre-loxP-mediated recombination to investigate the tissue-specific function of 
pVHL (Haase, Glickman et al. 2001). These studies provided some evidence 
that these mouse models can mimic mild clinical features of pVHL-associated 
human ccRCC; however, there are still substantial differences between the 
phenotype of these mouse models and human ccRCC as described below. 
 
Firstly, Vhl-deficiency in mouse germline cells causes cavernous liver 
hemangiomas, while it is a rare manifestation of ccRCC in human. This 
phenomenon is likely to be affected by polymorphic differences in related 
regulating genes, since the liver hemangiomas strongly depend on the genetic 
background of heterozygous mice as well (Ma, Tessarollo et al. 2003). It is also 
possible that, in Vhl-deficient mice, hepatocytes are particularly susceptible 
to loss or inactivation of their WT Vhl allele, leading to this liver phenotype 
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difference between mouse model and human disease (Haase, Glickman et al. 
2001).  
 
Secondly, another important ccRCC manifestation in human is kidney cysts, 
which are considered as precursor lesions of ccRCC. Kidney cysts occur 
frequently in human ccRCC cases (60 %), but very rare in Vhl-deficiency mice 
(<5 %) (Haase, Glickman et al. 2001). A possible explanation for this 
phenomenon is that there could be some additional genetic changes or 
mutation events besides Vhl mutation that are important for tumorigenesis. 
Multiple mutations may thus act cooperatively to drive cancer development.  
  
Taken together, it can be assumed that ccRCC development requires 
additional genetic events involving mutations in other tumor suppressor 
genes or oncogenes. Further studies are needed to test this hypothesis. 
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1.2 Brief overview of transcriptional regulation and the 
transcription factor HIF-α  
 
1.2.1 Brief overview of transcriptional regulation 
Transcriptional regulation is the dominating mode of regulation of gene 
expression and enables high specificity, diversity and complexity. It governs 
vast majority of biological processes such as development, cell differentiation 
and responses to physiological stimuli and cell signals. This mode of 
regulation decides what cellular proteins can be produced and thus 
determines how cells function and respond to the environment stimuli, a 
response which is critical for all the biological processes in the cells. 
Dysregulation of transcriptional regulation has been identified as a key cause 
of various disorders.  
 
There are multiple factors regulating successful mRNA transcription catalyzed 
by RNA polymerase II, including: general transcription factors, cofactors, 
histone and chromatin remodeling proteins, and most importantly, 
DNA-binding transcription factors (Lemon and Tjian 2000). As illustrated in 
Figure 1-2, the basic process of transcription initiation includes the following 
steps: firstly, the general transcription factors including TFII A, B and D and 
TBP protein bind to the TATA box in the promoter of DNA sequence; next, 
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other general transcription factors including TFII E, F and H join to form a 
transcription factor complex that can recruit RNA polymerase II (Buratowski, 
Hahn et al. 1989). Since this initiation complex is not able to increase or 
decrease the transcription rate alone, activators or repressors are required to 
bind to the enhancers within the DNA sequence, and thereby regulate the 
transcription rate and provide a variety of responses to different signals 
caused by internal or external stimuli (Dvir, Conaway et al. 2001). Chromatin 
remodelers as well as histone modifiers are also important regulators to 
modify the chromosome structure and to affect the accessibility of regulatory 
proteins to DNA, thereby regulating transcription (Spiegelman and Heinrich 
Figure 1-2 Diagram showing transcription initiation procedure. 
Firstly, the general transcription factors including TFII A, B and D 
and TBP proteins bind to the TATA box in the promoter of DNA 
sequence. Then other general transcription factors including 
TFII E, F and H join to form a full transcription factor complex 
that can recruit the RNA polymerase II. Diagram was generated 
by referring to “The processes of transcription and translation.” 
Boundless Anatomy and Physiology. Boundless, 25 Nov. 2014. 
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2004).  
 
Transcription factors are proteins that direct the binding of the transcription 
machinery containing RNA polymerase II to transcription start sites on 
genomic DNA. Multiple transcription factors recognize their cognate binding 
elements with specific DNA sequences, making precise and sophisticated 
transcriptional regulation possible. Considering the important regulatory role 
of transcription factors, it is understandable that the dysfunction of 
transcription factors can lead to numerous diseases including cancer (Furney, 
Higgins et al. 2006).  
 
There is a long list of transcription factors classified according to their types of 
DNA-binding domains. Our research interest focuses on two transcription 
factors that belong to the helix-loop-helix class, named hypoxia-inducible 
factor 1α and 2α (HIF-α). The functions of these transcription factors will be 
reviewed in the following paragraphs. 
 
1.2.2 The transcription factor HIF-α 
 General function of HIF-α 
As explained above, transcription factors can be important for sensing the 
stimuli from environment. As one typical example, HIF-1α and HIF-2α are 
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transcription factors that regulate the acute and chronic responses of the 
cells to hypoxia. Hypoxia denotes the oxygen level, which is lower than the 
normal physiological oxygen concentration. When there is insufficient oxygen 
supply or increased oxygen demand by tissues, cells can take advantage of 
stabilized cellular HIF-α protein to adapt to the hypoxic stress situation, 
through changing the HIF-α regulated biological process such as angiogenesis, 
metabolism, cell growth and cell differentiation, as reviewed above. When 
the stress withdraws, HIF-α activity diminishes immediately, and the 
downstream biological processes are adjusted accordingly. The HIF-α oxygen 
sensing mechanism allows cells to balance oxygen demand and supply, and to 
be adaptive to changes of micro environmental conditions.  
 
• HIF-α regulators 
As important sensors responding to hypoxia, HIF-α transcription factor is 
controlled by several regulators at both the post-translational level as well as 
the transcriptional level. This will be reviewed in the following paragraphs. 
 
The major machinery regulating HIF-α function is the pVHL E3 ubiquitin ligase. 
In normoxia, PHD1, 2 and 3 hydroxylate Pro402 and Pro564 of human HIF-1α 
or Pro405 and Pro531 of human HIF-2α (Bruick and McKnight 2001; Ivan, 
Kondo et al. 2001; Jaakkola, Mole et al. 2001; Masson, Willam et al. 2001; Yu, 
White et al. 2001), making it possible for the pVHL E3 ligase to recognize 
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HIF-α and subject to degradation. Since PHDs utilize the oxygen molecule, 
α-KG and Fe2+ as cofactors for the hydroxylation process, HIF-α function is 
precisely regulated by the oxygen concentration via the PHDs. 
 
In addition to this major regulating machinery, Whitelaw and colleagues have 
also identified another post-translational regulator of HIF-α named FIH1. FIH1 
is also an oxygen-dependent enzyme and hydroxylates Asn803 of human 
HIF-1α or Asn851 of human HIF-2α (Lando, Peet et al. 2002). This 
modification has been reported to block the binding of HIF-α to the 
transcription co-activator proteins p300/CBP, thereby preventing 
transcriptional activation of HIF-α target genes (Mahon, Hirota et al. 2001; 
Lando, Peet et al. 2002).  
 
Moreover, there are studies reporting that HIF-α protein levels can be 
regulated at the translational level by growth factors, cytokines and other 
signaling molecules, through PI3K or MAPK pathways (Zhong, Chiles et al. 
2000; Fukuda, Kelly et al. 2003). This fact indicates that HIF-α is not only 
involved in the response to oxygen concentration, but also other physiological 
stimuli.  
 
 HIF-α up-regulation in cancer 
Regarding the relationship between HIF-α and cancer, numerous reports have 
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shown that HIF-α is up-regulated in various cancer types. For example, Harris 
and colleagues reported that HIF-1α and HIF-2α were not detectable in 
normal tissues (except that HIF-2α was detected in bone marrow, which is 
known to represent a hypoxic environment); however, 50 % of malignant 
tumors from various cancer types including brain, breast, colon, ovarian and 
pancreatic cancer showed elevated HIF-1α and HIF-2α expression 
independent of VHL mutations (Talks, Turley et al. 2000). HIF-α expression 
levels also correlate with cancer grade as shown in a series of brain tumors 
(Zagzag, Zhong et al. 2000), and up-regulation of HIF-1α correlates with poor 
prognosis in cervical cancer (Birner, Schindl et al. 2000). It has also been 
shown that HIF-1α over-expression closely associates with human cancer 
metastases (Zhong, De Marzo et al. 1999). In ccRCC cases without functional 
pVHL, HIF-α and downstream targets can be constitutively detected, which is 
consistent with the fact that HIF-α is stabilized in the absence of functional 
pVHL (Krieg, Haas et al. 2000). Interestingly, in ccRCC tumors even at 
early-stage, HIF-α up-regulation can already be detected (Mandriota, Turner 
et al. 2002), indicating that pVHL loss of function and HIF-α activation are 
early events of ccRCC.  
 
 Phenotypes of mice with HIF-α xenograft 
Since HIF-α is found up-regulated in many cancer types, numerous of studies 
have addressed the question whether and how HIF-α acts as an oncogene. 
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For instance, several studies utilized transformed HIF-α knockout MEF cells 
for xenograft experiment and proved that these HIF-α knockout cells 
generated smaller tumor mass (Ryan, Poloni et al. 2000) and manifested 
higher rate of apoptosis (Unruh, Ressel et al. 2003), as well as showed 
reduced glucose metabolism under cell culture conditions (Seagroves, Ryan et 
al. 2001). Moreover, xenograft experiments have been performed using 
human cancer cells such as colon cancer cells, pancreatic cancer cells and 
ccRCC cells which are manipulated to over-express HIF-1α, and these 
experiments show a correlation between HIF-1α and angiogenesis, tumor 
growth and glucose metabolism (Ravi, Mookerjee et al. 2000; Akakura, 
Kobayashi et al. 2001), which are all critical cancer-related pathways. 
Moreover, Johnson and colleagues showed that deletion of HIF-1α in the 
mammary epithelium leads to decreased pulmonary metastasis in transgenic 
mouse model for metastatic breast cancer (Liao, Corle et al. 2007), indicating 
the important role of HIF-1α in cancer metastasis. The collective evidence 
demonstrates the crucial role of HIF-α in cancer homeostasis, growth and 
metastasis. 
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1.3 Regulation of cancer cell metabolism and the fatty acid 
synthase FASN  
 
1.3.1 Regulation of cancer cell metabolism 
Cancer metabolism is an active research field nowadays. Cancer cells favor 
stimulation of certain oncogenic signaling pathways and rely on certain 
metabolic alterations for survival and proliferation. Recently, accumulating 
evidence suggests a reciprocal relationship between oncogenic signaling 
pathways and metabolic changes in tumor cells: on one hand oncogenic 
signaling pathways regulate the function of metabolic enzymes, on the other 
hand metabolites and metabolic enzymes also affect oncogenic signaling 
pathways (Ward and Thompson 2012). Therefore, it is very interesting that 
metabolites and metabolic enzymes can have a significant contribution to 
cancer development.  
 
In order to fulfill the needs of survival and proliferation, cancer cells alter the 
amount or modifications of all four classes of macromolecules, including 
protein, lipids, nucleic acids and carbohydrates (Warburg 1956; Kuhajda 2000; 
Clemens 2004; Rahman, Voeller et al. 2004). Haase and colleagues reported 
neutral lipid accumulation in Vhl deficient mouse liver, by observing lipid 
vacuoles in these livers by Oil Red O staining (Haase, Glickman et al. 2001; 
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Rankin, Rha et al. 2009). Thus cancer-related lipid metabolism, in particular, 
fatty acid synthesis will be discussed here. 
 
Fatty acids are important biomaterials for the synthesis of triacylglycerides, 
phosphoglycerides, sterols and sphingolipids, which are further used to store 
energy, build biological membranes or function as hormones and secondary 
messengers in signal transduction. An interesting phenomenon is that normal 
cells and cancer cells have different levels of fatty acid synthesis. Most of the 
non-cancer cells (except for specialized tissues such as liver, adipose and 
lactating mammary glands etc.) directly use circulating lipids which are 
obtained from diet, and thus the endogenous fatty acid synthesis level in 
these cells is very low; in contrast, cancer cells show very high level of 
endogenous fatty acid synthesis, which indicates that the metabolites or 
enzymes related to fatty acid synthesis could be favored by cancer cells to 
obtain some oncogenic advantages (Weiss, Hoffmann et al. 1986; Kuhajda 
2000; Menendez and Lupu 2007).  
 
De novo fatty acid synthesis process in cancer cells includes a series of 
reactions that convert acetyl-CoA first to palmitate and subsequently into 
more complex fatty acids. Fatty acid synthase (FASN), the major biosynthesis 
enzyme, plays the most important role in this mode of lipogenesis. 
 
21 
 
1.3.2 The fatty acid synthase FASN 
 General function of FASN 
FASN is a multi-functional homodimeric protein consisting of seven catalytic 
domains. These domains are: thioesterase, acyl-carrier protein, β-ketoacyl 
reductase, enoyl reductase, β-hydroxyacyl dehydratase, acetyl/malonyl-CoA 
transferase, and β-ketoacyl synthase. The size of FASN is approximately 
250-270kDa. As the major enzyme in lipogenesis, FASN catalyzes the 
conversion of acetyl-CoA and malonyl-CoA into palmitate in the presence of 
NADPH (Chirala and Wakil 2004; Asturias, Chadick et al. 2005; Maier, 
Leibundgut et al. 2008). Besides its function as a main enzyme catalyzing de 
novo fatty acid synthesis, a lipogenesis-independent function of FASN has also 
been reported. One study showed that FASN can modulate Hepatitis C virus 
replication through its interaction with nonstructural protein NS5B (Huang, 
Tseng et al. 2013), indicating that FASN may have some 
lipogenesis-independent functions which remain to be identified and 
investigated. 
 
 FASN regulators  
FASN is known to be regulated at transcriptional level by the transcription 
factor sterol regulatory element binding protein-1 (SREBP1) (Rawson 2003; 
Eberle, Hegarty et al. 2004). Accumulating evidence has shown that in several 
cancer types, tumor cells can sense the growth factors and activate either the 
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PI3K-Akt signaling pathway (Van de Sande, De Schrijver et al. 2002; 
Kumar-Sinha, Ignatoski et al. 2003; Bandyopadhyay, Pai et al. 2005; Wang, 
Altomare et al. 2005) or the Ras-Raf-MEK-ERK1/2 signaling pathway (Yang, 
Han et al. 2002; Menendez, Mehmi et al. 2004; Menendez, Ropero et al. 
2004), eventually induce regulation of FASN expression by SREBP1. Moreover, 
there are also reports showing a potential connection between HIF-α and 
FASN. Haase and colleagues have shown that FASN mRNA levels are lower in 
liver tissue of the Vhl conditional knockout mice which, in turn, correlated 
with increased levels of HIF-2α (Rankin, Rha et al. 2009). Giaccia and 
colleagues have also shown that deletion of hepatic PHD3 in mice, leads to 
constitutive stabilization of HIF-2α and lower FASN mRNA levels than in 
control mice (Taniguchi, Finger et al. 2013). Although studies on genetically 
modified mice often provide robust evidence, it is not clear from these 
studies whether and how HIF-2α regulates FASN in other cell types or in 
cancer. 
 
There are also reports showing that FASN is regulated at the 
post-translational level. It has been demonstrated that the ubiquitin-specific 
protease-2a (USP2a) de-ubiquitinates FASN in prostate cancer cells (Graner, 
Tang et al. 2004). As de-ubiquitination and ubiquitination are reversible 
processes, another group recently identified an E3 ligase COP1 responsible of 
the ubiquitination of FASN (Yu, Deng et al. 2013), although these mechanisms 
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still remain to be further elucidated. Therefore, it is still possible that other E3 
ligases may play a role in the post-translational regulation of FASN. 
 
 Up-regulation of FASN in cancer 
Many studies have reported the correlation between up-regulation of FASN 
and poor prognosis in various cancer types including prostate, colon, breast, 
lung, ovarian and endometrial cancer (Alo, Visca et al. 1996; Gansler, 
Hardman et al. 1997; Rossi, Graner et al. 2003; Sebastiani, Visca et al. 2004; 
Visca, Sebastiani et al. 2004; Ogino, Nosho et al. 2008). Furthermore, several 
studies have suggested that FASN is a bona fide oncogene, which plays very 
important role in carcinogenesis (Pizer, Thupari et al. 2000; Kridel, Axelrod et 
al. 2004; Migita, Ruiz et al. 2009). FASN is considered as a promising drug 
target, and several groups have tried to develop cancer therapeutic inhibitors 
targeting FASN (Currie, Schulze et al. 2013; Zhao, Butler et al. 2013) 
 
The mechanisms of how FASN may function as an oncogene has been 
explored by some researchers but still remains poorly understood. It has been 
hypothesized that the fatty acid synthesized by FASN would be used for 
unique functions in cancer cells (Menendez and Lupu 2007). However, 
contradictory results were reported that in breast cancer cells, the fatty acids 
synthesized by FASN do not have any special function to provide oncogenic 
advantages for these cancer cells (Hopperton, Duncan et al. 2014). This 
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indicates that FASN may have some unknown functions independent from its 
fatty acid synthesis function, which may be critical for the survival and 
proliferation of cancer cells. 
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1.4 Epigenetic modifications regulating gene expression and the 
H3K27 demethylase UTX  
 
1.4.1 Epigenetic modifications regulating gene expression 
The basic unit of chromatin is nucleosomes, and the nucleosome core is 
composed of histone H1 and two copies of the histones H2A, H2B, H3 and H4, 
which pack the DNA into a tight structure. To enable transcription, the dense 
chromatin must be loosened to allow the transcriptional machinery to access 
DNA. In general, certain histone modifications correlate with chromatin 
remodeling and transcriptionally active or repressive states of chromatin 
(Horn and Peterson 2002).  
 
Histone N-terminal tails are subjected to several post translational 
modifications, including methylation, phosphorylation, acetylation and 
ubiquitination (Strahl and Allis 2000). Regarding histone methylation, 
unmethylated lysines in the histone tails can be methylated into three 
statuses: monomethylation, dimethylation or trimethylation. Different 
methylation statuses could result in different conformational changes in the 
chromatin, and potentially determine different transcriptional activities of 
genes associated with these regions of chromatin. Among the many histone 
methylation modifications, methylation of H3 Lys 4, 9 and 27 have been 
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relatively well-studied and found to be important for gene regulation. H3K9 
and H3K27 trimethylation usually correlate with transcriptional repression 
while H3K4 trimethylation correlates with transcriptional activation. We have 
focused on the above-mentioned modifications since they are related to 
tumorigenesis (Chi, Allis et al. 2010).  
 
Adding or removing methyl groups on the lysine residues is regulated by 
specific methyltransferases and demethylases, allowing dynamic changes in 
the methylation status. The known methyltransferases and demethylases of 
H3K4, K9 and K27 are shown in Figure 1-3 below. 
 
Among these methyltransferases and demethylases, we have paid special 
attention to Ubiquitously Transcribed X Chromosome Tetratricopeptide 
Repeat Protein (UTX), Jumonji Domain Containing 3 (JMJD3), polycomb 
Figure 1-3 Diagram showing the methyltransferases and 
demethylases of histone H3K4, K9 and K27. UTX and JMJD3 are 
major H3K27 demethylases that correlate with transcriptional 
activation. MLL2 is a H3K4 methyltransferase that also correlate 
with transcriptional activation. 
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repressive complex 1 and 2 (PRC1 and PRC2) and  Myeloid/Lymphoid Or 
Mixed-Lineage Leukemia 2 (MLL2) proteins. UTX and JMJD3 are major H3K27 
demethylases that correlate with transcriptional activation. So far only these 
two have been well characterized as H3K27 demethylases (Agger, Cloos et al. 
2007; Hong, Cho et al. 2007; Lan, Bayliss et al. 2007). Two different polycomb 
group complexes have been identified: PRC2 with H3K27 methyltransferase 
activity and PRC1 with binding activity to both H3K27me3 and H3K9me3 
residues (Bernstein, Duncan et al. 2006). In a concerted manner, PRC2 and 
PRC1 exert antagonizing activity to UTX and correlate with transcriptional 
repression. MLL2 protein is H3K4 methyltransferase that correlates with 
transcriptional activation of target genes. In general, dysregulation of these 
modifiers is closely related to tumorigenesis. For example, the polycomb 
complex components BMI1 and EZH2 are well-established as oncogenes 
(Bracken and Helin 2009). Interestingly, UTX gene mutations (loss of function) 
have been newly identified in many human cancers including ccRCC by 
several large-scale sequencing studies (Dalgliesh, Furge et al. 2010). This 
novel finding intrigued our interest since very limited studies have been 
performed to understand UTX function regarding tumorigenic events. 
 
1.4.2 The H3K27 demethylase UTX  
 General function of UTX 
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UTX is a 150kDa protein encoded by the UTX gene which is located on the X 
chromosome and largely escapes X inactivation (Greenfield, Carrel et al. 
1998). The UTX protein contains two functional domains, including the 
catalytic JmjC domain and the protein-binding tetratricopeptide repeat (TPR) 
domain. Regarding the demethylase activity of UTX, Ge Kai and colleagues 
demonstrated that UTX has the ability to demethylate H3K27me2 and 
H3K27me3 (Hong, Cho et al. 2007) depending on its JmjC domain, and 
Yokoyama provided the structural basis for this process by deciphering the 
physical interaction between the UTX JmjC domain and substrates, to 
understand its catalytic ability (Sengoku and Yokoyama 2011). Several studies 
have reported that UTX is detected in the MLL2-containing H3K4 
methyltransferase complex (Agger, Cloos et al. 2007; Hong, Cho et al. 2007), 
suggesting functional connection between H3K27 demethylation and H3K4 
methylation. However, it still remains poorly understood.  
 
Like other epigenetic modifiers, UTX plays an important role in embryonic 
development. For instance, homozygous mutation of the Drosophila UTX 
ortholog suppresses sex comb modifications through affecting the function of 
HOX genes (Herz, Madden et al. 2010). Moreover, the C. elegans UTX 
ortholog regulates developmental fate decisions via the RB protein complex 
(Wang, Tsai et al. 2010). More interestingly, UTX has recently been indicated 
by several sequencing studies to have a potential role in tumorigenic events, 
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which will be reviewed in the following paragraph. 
 
 UTX mutations in cancer 
Since 2009, several groups have performed genome-wide and exome 
sequencing and reported UTX mutations in more than twelve types of cancers, 
as extensively reviewed (van Haaften, Dalgliesh et al. 2009; Dalgliesh, Furge et 
al. 2010; Chapman, Lawrence et al. 2011; Gui, Guo et al. 2011; Grasso, Wu et 
al. 2012; Jones, Jager et al. 2012; Mar, Bullinger et al. 2012; Kandoth, 
McLellan et al. 2013; Ross, Wang et al. 2014). Futreal and colleagues were the 
first to identify UTX loss-of-function mutations in solid and hematologic 
tumors including leukemia, multiple myeloma, esophageal and renal cell 
carcinoma etc. (van Haaften, Dalgliesh et al. 2009). In the same study, they 
presented preliminary evidence that UTX functions as a tumor suppressor by 
observing reduced proliferation in UTX over-expressing cells (van Haaften, 
Dalgliesh et al. 2009). However, evidence still remains inadequate to confirm 
the tumor suppressor function of UTX. Particularly, the function of 
cancer-related UTX mutations needs to be investigated, which could provide 
an understanding of the underlying mechanism. 
 
 Phenotype of Utx knockout mice 
So far only constitutive Utx knockout mice have been established, showing 
embryonic lethality before E11.5 (Shpargel, Sengoku et al. 2012; Wang, Lee et 
30 
 
al. 2012). Cardiac and neural developmental abnormalities (underdeveloped 
heart and unclosed neural tubes) were reported to be the reason causing 
embryonic lethality (Shpargel, Sengoku et al. 2012). These observations 
indicate that UTX is essential for early embryonic development. 
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Objectives and hypotheses of the study 
The objective of this study is to have a deeper understanding of pVHL 
function in tumorigenesis. Some potential models were hypothesized, as 
shown in Figure 1-4. By identifying novel pVHL interacting proteins, some 
novel targets (Figure 1-4 A) or regulating factors (Figure 1-4 B) of pVHL E3 
ligase can be revealed, and these interactions may have pathophysiological 
significance in tumorigenesis. Moreover, according to recent publications, 
some novel gene mutations were identified with high prevalence in ccRCC 
(van Haaften, Dalgliesh et al. 2009; Dalgliesh, Furge et al. 2010). Thus, 
another hypothesis was raised that these novel mutations may function 
independently, synergistically or in a compensatory manner with VHL 
mutations, eventually triggering ccRCC (Figure 1-4 C). These hypotheses were 
tested in two parts in this study, as presented in the following chapters. 
 
Figure 1-4 Diagram showing the proposed hypotheses in this study. 
Novel pVHL targets, regulating factors or cooperating factors may 
function synergistically or independently from pVHL function, to have 
a consequence on tumorigenesis. 
32 
 
 
 
 
 
 
 
 
 
 
  
33 
 
Chapter 2 Materials and methods 
2.1 Cell based assays 
2.1.1 Cell lines and cell culture conditions  
The following cell lines were used in this project: 
HCT116 (human colon cancer cell line, ATCC) 
786-O (human ccRCC cell line, ATCC) 
A498 (human ccRCC cell line, ATCC) 
SKRC10 (human ccRCC cell line, a gift from Karolinska Institutet) 
HeLa (human cervical cancer cell line, ATCC) 
HepG2 (human hepatocellular carcinoma cell line, ATCC) 
293T (human embryonic kidney cell line, ATCC) 
PREC (human primary renal epithelial cell line, ATCC) 
3T3-L1 (mouse embryonic fibroblast cells, ATCC) 
MLC (mouse primary liver cells, obtained from mouse liver) 
flox-Vhl MEF cells (mouse embryonic fibroblast cells obtained from 
Vhl knockout mice, a generous gift from Prof. Randall Johnson) 
Human cells (HCT116, 786-O, A498, SKRC10, HeLa, HepG2 and 293T), 
and mouse cells (3T3-L1, MLC and MEF) were cultured in DMEM 
(Nacalai) supplemented with 10 % FCS, GlutaMAX and 
penicillin/streptomycin (Invitrogen). PREC cells (ATCC, PCS-400-012) 
34 
 
were cultured in Renal Epithelial Cell Basal Medium (ATCC) 
supplemented with Renal Epithelial Cell growth kit (ATCC). 3T3-L1 
cells (ATCC, CL-173TM) were cultured and differentiated with insulin, 
dexamethasone, and 3-isobutyl-1-methylxanthine (IBMX) (Sigma). All 
the cells were maintained in monolayer at 37 °C in 5 % CO2 incubator.  
2.1.2 Oxygen conditions 
Hypoxia cell culture conditions (1 % or 0.1 % O2, 5 % CO2 and 
balanced with N2) were achieved using an INVIVO2 400 hypoxia 
workstation (Ruskinn).  
2.1.3 Anchorage-independent colony formation 
Each well of a 12-well culture plate was coated with bottom agar 
mixture (DMEM with 10 % FCS and 0.5 % agar). After the bottom 
layer had solidified, top agar mixture (DMEM with 10 % FCS and 
0.35 % agar) containing 2×103 cells was added to each well, and 
cultured at 37 °C in a 5 % CO2 incubator. Colony formation was 
monitored daily with a light microscope. After incubation for 2-3 
weeks, colonies in soft agar were stained with crystal violet and 
photographed by an Olympus SZX12 dissecting microscope. The 
software ImageJ was used for imaging processing and analysis.  
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2.1.4 Anchorage-independent spheroid formation 
1×103 cells were plated in low attachment 6-well culture plate and 
cultured in DMEM supplemented with 10 % FCS at 37 °C in a 5 % CO2 
incubator. Spheroid formation was photographed after 5 days by an 
Olympus SZX12 dissecting microscope. ImageJ was used for imaging 
processing and analysis.  
2.2 DNA manipulation 
2.2.1 Site-directed mutagenesis 
Point mutations were introduced into plasmids using the 
QuickChange II XL Site-directed Mutagenesis Kit (Stratagene), 
according to manufacturer’s instruction. A pair of complemented 
primers was designed with mutant codon in the middle of the 
primers. 50 μl PCR reaction included 10 ng of dsDNA template, 125 
ng of primers, 1 μl of dNTP mix, 3 μl of QuikSolution, 5 μl of 10× 
reaction buffer and 1 μl of PfuUltra HF DNA polymerase. PCR cycling 
parameters were set as 95 °C 1 min for 1 cycle, 95 °C 50 sec, 60 °C 50 
sec, 68 °C 1 min/kb of plasmid length for 18 cycles, and 68 °C 7 min 
for 1 cycle. PCR products were then treated with DpnI at 37 °C for 1 h 
to digest the methylated wild-type parental DNA template. The 
newly synthesized mutated plasmids were transformed into E. coli 
36 
 
for subsequent colony selection and DNA sequencing. 
2.2.2 DNA plasmid transfection  
Transient transfection was performed with Lipofectamine 2000 (Life 
Technologies) according to manufacturer’s instruction. Cells were 
seeded in 10 cm dish to reach 80 % confluency in 24 h prior to 
transfection. 16-18 μg of plasmid DNA as well as 40-45 μl of 
Lipofectamine 2000 were mixed with opti-MEM respectively for 5 
min and the two diluents were then combined and incubated for 20 
min and added into each dish. The transfection mixture was replaced 
by fresh complete medium after 6 h and cells were harvested 48 h 
after transfection. 
2.2.3 Lentivirus vector preparation and stable cell line establishment 
Lentiviral vectors for the expression of cDNA were prepared by 
standard protocol (Demaison, Parsley et al. 2002; Strang, Ikeda et al. 
2004; Tiscornia, Singer et al. 2006). Briefly, 293T cells were seeded in 
T75 flask to reach 90 % confluency in 24 h prior to transfection. 5 μg 
of the vector plasmid (CSII-CMV-IRES2-venus or CSII-CMV-RSV-venus) 
was co-transfected with 8 μg p8.91 or 5 μg of pMDLg/pRRE + 3 μg of 
pRSV-Rev together with 3 μg of additional plasmid pMD2.G, using 
Lipofectamine 2000 as described above. The supernatant containing 
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virus was harvested twice in 48 h and 72 h after transfection. The 
supernatant was then filtered through 0.45 μm filter unit and 
concentrated by centrifugation for 60 min at 10,000 g. Recipient cells 
were seeded in 12-well plate 24 h prior viral infection. 200 μl of 
supernatant was used for infection for 3 h in the presence of 10 
μg/ml polybrene. Integration efficiency of lentivirus was monitored 
by GFP fluorescence for CSII-CMV-IRES2-venus or 
CSII-CMV-RSV-venus. To obtain cells expressing low levels of 
exogenous protein, the CMV promoter or enhancer was replaced 
with a minimum HIV promoter. For shRNA expression, MISSION 
lentivirus vector pLKO.1 was used (Sigma-Aldrich) and stably 
shRNA-expressing cells were obtained by selection with puromycin. 
2.2.4 CRISPR/Cas9 knockout 
To stably inactivate or suppress gene expression, the gene editing 
strategy called CRISPR/ was employed. Viruses to express sgRNA and 
Cas9 were prepared from lenti CRISPR/Cas9 plasmid (Cong, Ran et al. 
2013). After infection and selection with puromycin, cells were 
plated on a 15 cm dish. Colonies were isolated in 2 weeks and 
expression was analyzed by western blot analysis.    
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2.3 RNA manipulation 
2.3.1 siRNA transfection 
Transfection was performed with DharmaFECT (Dharmacon) 
according to manufacturer’s instruction. 6.5104 cells were seeded 
in 12-well plate in 24 h prior to transfection. 2.5 μl of 20 μM siRNA 
(Dharmacon) as well as 1.5-2.5 μl of DharmaFECT 1 or 2 were mixed 
with opti-MEM respectively for 5 min and the two diluents were 
combined and incubated for 20 min before being added into each 
well. The transfection mixture was replaced by fresh complete 
medium after 6 h and cells were harvested 72 h after transfection.  
2.3.2 RNA extraction 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instruction. 600 μl buffer RLT containing 
1 % β-ME was used to lyse the cells in dish directly. Lysates were 
homogenized by passing through Qiashredder (Qiagen). Equal 
volume of 70 % ethanol was then added to the lysate and the 
mixture was passed through the RNeasy Mini spin column. Column 
was then washed by buffer RW1 once and buffer RPE twice. Finally, 
60 μl of RNase-free water were used to elute the RNA. RNA 
concentration and purity were assessed with Nanodrop ND-1000. 
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2.3.3 cDNA synthesis and qPCR analysis 
cDNA synthesis was conducted with up to 1 μg of total RNA, using 
the iScript cDNA synthesis Kit (Bio-Rad) according to manufacturer’s 
protocol. Then cDNA samples were amplified using KAPA SYBR FAST 
qPCR Kit (Kapa Biosystems), in 384-well plates and detected by the 
7900HT Fast Real-Time PCR system (Applied Biosystems).  qPCR 
cycling parameters were set as 1 cycle of 95 °C for 3 min, 40 cycles of 
95 °C 3 sec then 60 °C 30 sec, and 1 cycle of 95 °C 15 sec, 60 °C 15 
sec and 95 °C 15 sec. Primers used were listed in Table 2-1.  
 Forward Reverse 
VEGFA AGGAGGAGGGCAGAATCATCA CTCGATTGGATGGCAGTAGCT 
PGK1 AGATTCAGCTAGTGGCCAAGAG TGCAGTGAAGATGAGCTGAGAT 
SLC2A1 GGAGCCCAGCAGCAAGAAG ACTGCAGGGAGCCAAGCA 
ADM CCCTGATGTACCTGGGTTCG GCCCACTTATTCCACTTCTTTCG 
CA9 TGCCTATGAGCAGTTGCTGTCT CAGTCCTGGGACCTGAGTCTCT 
KDM3A ACTGCTTCTGGCTTACTCAGG TCACTGGCTTTCAGCATAGCA 
MXI1 GATTCAGAGCGAGAGGAGATTG ACACTGGCACTGGAGTAACC 
REDD1 GAACTCCCACCCCAGATCGG CGAGGGTCAGCTGGAAGGTG 
HK2 GATTGTCCGTAACATTCTCATCGA TGTCTTGAGCCGCTCTGAGAT 
PDK1 ATTCAAGTTCATGTCACGCTGG TTTCCTCAAAGGAACGCCAC 
PKM2 GCCTGCTGTGTCGGAGAAG CAGATGCCTTGCGGATGAATG 
HIF-1α TTCCAGTTACGTTCCTTCGATC TTTGAGGACTTGCGCTTTCA 
HIF-2α GTGCTCCCACGGCCTGTA TTGTCACACCTATGGCATATCA 
FASN CATCCAGATAGGCCTCATAGAC CTCCATGAAGTAGGAGTGGAAG 
PPIA ACGGCGAGCCCTTGG TTTCTGCTGTCTTTGGGACCT 
2.3.4 Microarray analysis 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and 
Table 2-1 qPCR primer sequences. 
40 
 
reverse transcribed into cDNA and in vitro transcribed into 
biotin-labeled cRNA using the Illumina TotalPrep RNA Amplification 
kit (Ambion). The cRNA probe was hybridized to MouseRef-8 v2.0 
Expression BeadChip microarrays (Illumina) and scanned on the 
BeadArray Reader (Illumina). Raw intensity values were subjected to 
background subtraction on the BeadStudio Data Analysis Software 
(Illumina) and normalized using the cross-correlation method. 
Differential gene expression was identified based on a fold change 
cut-off of >1.5 compared to the control. 
2.3.5 Gene ontology analysis 
Gene names together with the fold change values obtained from 
microarray analysis were input into Ingenuity Pathway Analysis (IPA 
Ingenuity Systems, www.ingenuity.com). The information of enriched 
signaling pathways and biological functions were obtained from this 
analysis.  
2.4 Protein manipulation 
2.4.1 Total protein extraction 
Cells cultured in 10 cm or 15 cm dish were washed twice with 
ice-cold PBS in the dish and collected by cells scraper. Cell pellet was 
then suspended and lysed with six volumes of M-PER (Thermo) 
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containing 1mM PMSF and Complete protease inhibitor (Roche). 
Cells cultured in 12-well plate or 6-well plate were washed twice 
with ice-cold PBS in dish and lysed by 100 μl or 250 μl M-PER 
containing 1 mM PMSF and Complete protease inhibitor (Roche), 
and then collected by cell scraper. Lysates were then rotated in the 
cold room for 20 min and centrifuged at 12,000 rpm for 15 min at 
4 °C. Supernatant was recovered for experiments. 
2.4.2 Immunoprecipitation of Flag-tagged proteins 
Cell extracts were incubated 4 h or overnight with anti-Flag M2 
beads (α-Flag Tag monoclonal antibody-conjugated Sepharose beads) 
(Sigma) in cold room, with end-to-end rotation (e.g. 30 μl settled 
beads to 20 mg/10 ml cell extract). Beads were washed twice with 
buffer WG (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM NaF, 1 mM 
EDTA, 1 % Triton X 100, 0.2 % Sarkosyl, 10 % Glycerol, protease 
inhibitors) and then twice with buffer D-300 (20 mM Tris pH 8.0, 300 
mM NaCl, 0.5 mM EDTA, 10 % Glycerol, 0.5 % NP40, protease 
inhibitors) to remove unbound proteins. Immunoprecipitated 
proteins were eluted by adding two volumes of 250 μg/ml Flag 
peptide diluted in buffer D, in cold room for 20 min with gentle 
agitation. 
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2.4.3 Immunoprecipitation of endogenous proteins 
G Sepharose beads (GE) were incubated with antibody (specific 
antibody or control IgG) in 4 °C for 4 h, treated by blocking with 0.5 % 
BSA in 4 °C for additional 30 min, and incubated with cell extract in 
cold room for 4 h, with end-to-end rotation (e.g. 10 μl settled beads 
to 2.5 μg antibody to 3 mg/1 ml cell extract). Beads were washed 
twice with buffer WG and then twice with buffer D to remove 
unbound proteins. Immunoprecipitated proteins were eluted by two 
volumes of 1 % SDS buffer in 50 °C for 10 min. 
2.4.4 Immunofluorescence 
Cells were seeded in 8-well Lab-Tek chamber slides (Thermo) to 
reach 50 % confluency 24 h prior to staining. Cells were fixed with 4 % 
paraformaldehyde for 10 min, permeabilized for 15 min with 0.1 % 
NP40 PBS solution, and blocked with blocking solution (5 % BSA and 
0.3 % Triton X-100 in PBS) for 20min. Primary antibody was diluted to 
1:200 with binding solution (1 % BSA and 0.3 % Triton X-100 in PBS) 
and incubated overnight, followed by incubation with Alexa Fluor 
488 or 568-conjugated secondary antibody at 1:200 with binding 
solution for 1 h at room temperature. After sufficient washing with 
PBS, Prolong Anti-Fade mounting solution containing DAPI was 
added (Invitrogen). Slides were then covered with coverslip and 
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sealed with nail polish. Fluorescence images were then observed and 
captured by Nikon A1R confocal microscope, with 20×, 40× or 60× 
objectives. 
2.4.5 Western blotting 
Protein samples of cell lysates or immunoprecipitates were mixed 
with sample buffer and boiled at 95 °C for 5 min. Equal amounts of 
protein samples (10-30 μg) were loaded and separated by 6 %, 8 % 
or 16 % SDS-polyacrylamide gels at 120 V for 1.5 h with an 
electrophoresis apparatus (Bio-Rad) and subsequently transferred 
onto PVDF membrane (Millipore) using a wet transfer apparatus 
(Bio-Rad) at 40 V for 6 h or 45 V for 2 h. Membranes with 
immobilized proteins were blocked with 5 % milk (Nacalai), 
suspended in 0.1 % PBST (0.1 % TWEEN 20 in PBS) for 30 min, and 
then incubated with primary antibody for 2 h or overnight. After 
washing for 15 min with 0.1 % PBST, the membranes were incubated 
with HRP-conjugated secondary antibody for 40 min. All antibodies 
were diluted in 5 % milk. After washing for 40 min with 0.1 % PBST, 
the membranes were incubated with chemoluminescent ECL 
substrate (Amersham/PerkinElmer) and detected with X-ray films 
(Konica).  
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2.4.6 Primary antibodies 
Western blot experiment was performed with the following primary 
antibodies: Actin antibody (A5441) and Flag M2 antibody (F1804) 
from Sigma; HIF-1α antibody (NB100-479) from NOVUS; HIF-1α 
antibody (GTX127309) and UTX antibody (GTX121246) from GeneTex; 
pVHL antibody (#2738), FASN antibody (#3180) HIF-2α antibody 
(#7096) and Ubiquitin antibody (#3936) from Cell Signaling; pVHL 
antibody (sc-11780), Elongin C antibody (sc-135895), CUL2 antibody 
(sc-166506) and SREBP1 antibody (sc-366) from Santa Cruz; CAD 
antibody (ab40800) and RNA polymerase II antibody (ab5408) from 
Abcam; ASH2 antibody (39099) from Active Motif; H3 antibody 
(#06-755) from Millipore; H3K4me2 antibody (308-34809), H3K9me2 
antibody (302-32369) and H3K27me3 antibody (309-95259) from 
Waco. 
Immunofluorescence staining and immunoprecipitation experiments 
were performed with the following primary antibodies: pVHL 
antibody (556347) from BD Pharmingen; FASN antibody (#3180) 
from Cell Signaling. 
2.4.7 Secondary antibodies 
Western blot experiment was performed with the following 
secondary antibodies: ECL Mouse or Rabbit horseradish peroxidase 
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linked antibody (GE). 
Immunofluorescence staining experiment was performed with the 
following secondary antibodies: Alexa Fluor 488/568-conjugated 
Mouse or Rabbit antibody (Invitrogen). 
2.4.8 In vitro de-ubiquitination assay 
The de-ubiquitination assay was conducted according to Table 2-2 
below: 
 
 1 2 3 
5x reaction buffer 
(0.5 M Tris pH7.5, 5mM DTT, 
5mM EDTA) 
6 μl 6 μl 6 μl 
HCT116 F-pVHL pull down eluate 12 μl 12 μl 12 μl 
USP2a buffer same 
volume 
as USP2a 
- - 
USP2a - 0.5 μg 0.5 μg 
Ubiquitin aldehyde - - 2.5 μg 
NaOH - - 0.02 N 
NaCl 0.02 N 0.02 N - 
BSA 5 μg 5 μg 5 μg 
H2O was used to top up to final 30 μl reaction system.  
All the three samples were incubated at 37 °C for 30 min. 
2.4.9 Mass spectrometry 
Eluates from immunoprecipitation were separated on pre-casted 10 % 
or 4-20 % SDS-polyacrylamide gels (Bio-Rad) and stained with 
Table 2-2 De-ubiquitination assay. 
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Coomassie Brilliant Blue R-250 (Bio-Rad) or Zinc/Imidazole (Thermo) 
according to manufacturer’s instruction. Excised gel slices were 
analyzed by LC-MS/MS Mass Spectrometry analysis (ProtTech). 
Proteins identified at high scores (with > 30 % of relative identified 
peptide numbers within a sample) were taken into consideration and 
common contaminants were excluded. Identified proteins were 
verified by western blot analysis.  
2.5 Data representation 
2.5.1 Graphs 
Graphs were prepared using Excel and Graphpad prism 5.  
2.5.2 Images 
Olympus SZX12 dissecting microscope or Nikon A1R confocal 
microscope was used to obtain photos. ImageJ was used for imaging 
processing and analysis.  
2.5.3 Statistical analyses 
Statistical analysis was performed using GraphPad prism 5. Student’s 
t-tests were utilized to calculate p-values. 
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Chapter 3 Regulation of HIF-α through 
pVHL-FASN interaction 
 
3.1 Results 
As outlined above, it is likely that unidentified pVHL-interacting proteins also 
have regulatory roles in cancer development. In this project, FASN has been 
identified as a novel pVHL interacting protein, and the function of FASN on 
the pVHL-regulated hypoxia signaling pathway turns out to be a new 
regulatory mechanism. 
 
 
3.1.1 Physical interaction between pVHL and FASN 
Summary  
As shown in this section, FASN was identified as a novel pVHL interacting 
protein (Figure 3-1) and the interaction between endogenous FASN and pVHL 
was confirmed (Figure 3-2). We established that FASN is ubiquitinated, but 
pVHL may not be the major E3 ligase responsible for the ubiquitination of 
FASN (Figure 3-3). The FASN C-terminal region was shown to be important for 
the interaction with pVHL (Figure 3-4); while the pVHL mutant Y112H lost the 
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ability to interact with FASN (Figure 3-5, Figure 3-6). Our study is the first 
report to show the interaction between FASN and pVHL.  
 
 
• FASN is a novel pVHL interacting protein. 
To identify novel pVHL interacting proteins, immunoprecipitation and mass 
spectrometry (LC-MS/MS) analysis were conducted according to the 
A B 
Figure 3-1 FASN is a novel pVHL interacting protein. (A) Procedures to 
identify novel pVHL interacting proteins are shown in this flow chart. 
Flag-tagged pVHL was stably expressed in HCT116 cells by lentiviral 
vectors, while plain HCT116 cells were used as control. Cells were 
treated with 10 μM of the proteasome inhibitor MG132 overnight and 
lysed for immunoprecipitation using α-Flag-tag-conjugated M2 beads. 
The eluate was separated by SDS-PAGE and subjected to silver staining 
to visualize any specific bands. Bands of interest were excised and 
analyzed by mass spectrometry. (B) Silver staining of an SDS-PAGE gel 
showed the specific pVHL interacting proteins, which were confirmed by 
mass spectrometry analysis. In particular, FASN and CAD were identified 
as novel pVHL interacting proteins from a gel slice containing a major 
protein band at 250kD.  
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procedures summarized in Figure 3-1 A. In this experiment, HCT116 cells 
stably expressing Flag-tagged pVHL by a lentiviral vector (HCT116 F-pVHL cells) 
were utilized, because the HCT116 cell line has high response to hypoxia and 
cell extract preparation is readily feasible.  
 
As shown in the silver staining result (Figure 3-1 B), pVHL as well as other 
known pVHL-interacting proteins including CUL2, Elongin B, Elongin C, HIF-1α, 
HIF-2α and Chaperonin components were detected as major bands and at 
high score in the mass spectrometry analysis. This finding is in agreement 
with previous reports (Kibel, Iliopoulos et al. 1995; Pause, Lee et al. 1997; 
Feldman, Thulasiraman et al. 1999; Maxwell, Wiesener et al. 1999). 
Interestingly, critical metabolic enzymes, FASN and CAD, were coincidentally 
identified as novel pVHL-interacting proteins, from a specific band at 250kD 
Table 3-1 Mass spectrometry results showed that FASN and CAD were 
identified as novel pVHL interacting proteins. FASN and CAD were 
identified with high peptide numbers from two independent 
experiments. 
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(Table 3-1). CAD, which is the abbreviation of the carbamoyl phosphate 
synthase - aspartate transcarbamylase - dihydroorotase, is responsible for 
pyrimidine biosynthesis (Davidson, Chen et al. 1993). Since we are focusing 
on FASN in this project, we have not investigated the functional importance of 
the interaction between CAD and pVHL, which might be a potential future 
project. As reviewed above, FASN is a key enzyme responsible for fatty acid 
synthesis. In particular, up-regulation of the FASN protein in various cancer 
types attracted our attention. However, how FASN can function as an 
oncogene still remains unknown. Thus, we were prompted to investigate the 
interaction between FASN and pVHL to provide any mechanism for this 
research question.  
 
 
• pVHL interacts and co-localizes with endogenous FASN in human cancer 
cells. 
Firstly, to validate the interaction between pVHL and FASN, endogenous 
immunoprecipitation was performed in HCT116 cells. The results showed that 
pVHL was successfully detected in the FASN complex (Figure 3-2 A, right 
bottom panel) and vice versa (Figure 3-2 A, left top panel). Comparing to the 
input amount, it can be seen that only a portion of the total cellular FASN 
protein was interacting with pVHL, which could mean that pVHL is a 
low-abundant cellular protein and thus limiting. Another interesting finding 
was that FASN was also present in the CAD pull-down complex at the 
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endogenous level, as shown in Figure 3-2 B, suggesting the possibility that 
FASN and CAD may function in cooperation with each other to form a super 
metabolic complex and join the fatty acid synthesis with the pyrimidine 
biosynthesis, which remains to be studied as a future project. 
 
Secondly, to validate the cellular co-localization between pVHL and FASN, 
Figure 3-2 pVHL interacts and co-localizes with endogenous FASN in human 
cancer cells. (A) pVHL interacted with endogenous FASN in HCT116 cells. 
HCT116 cells were treated with 10 μM MG132 overnight, and lysed for 
immunoprecipitation using pVHL or FASN antibodies (IgG as control). 
Western blot analysis was conducted using pVHL or FASN antibodies to 
validate the interaction between pVHL and FASN at the endogenous level. 
(B) CAD was identified in the FASN protein complex. Eluates from Figure 3-2 
A as well as eluates from endogenous immunoprecipitation using CAD 
antibody were used for western blot analysis. (C) pVHL co-localized with 
endogenous FASN in HeLa cells. Immunofluorescence staining was done 
using pVHL (green fluorescence) and FASN (red fluorescence) antibodies in 
HeLa cells, followed by confocal microscopy.  
 
 
 
 
A 
B 
C 
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immunofluorescence staining was performed with anti-pVHL (green 
fluorescence) and anti-FASN (red fluorescence) antibodies in HeLa cells. The 
results showed that pVHL and FASN predominantly co-localized in the 
cytoplasm for most of the HeLa cells (Figure 3-2 C, row 1 and row 2). However, 
in a small cell population, pVHL localized predominantly in the periphery of 
the nuclear membrane, and the incidence of co-localization is lower (Figure 
3-2 C, row 3). It has been shown that pVHL mainly localizes in cytoplasm but 
shuttles between nucleus and cytoplasm depending on cell density (Lee, 
Chen et al. 1996; Zheng, Ruas et al. 2006). It has also been reported that 
pVHL has multiple functions which are either dependent or independent of 
HIF-α, such as regulation of microtubule stability (Thoma, Toso et al. 2009) as 
reviewed above. Thus, these mechanisms could account for the dynamic and 
heterogeneous subcellular localization of pVHL. 
 
 
• Possibility of FASN ubiquitination by the pVHL E3 ligase. 
As summarized above, pVHL functions as a component of an E3 ligase 
complex, and can target substrates other than HIF-α (Okuda, Saitoh et al. 
2001; Li, Na et al. 2002; Na, Duan et al. 2003; Gamper, Qiao et al. 2012). Since 
we detected modified FASN bands of higher molecular weight (Figure 3-3 A 
top panel), we considered the possibility that FASN ubiquitination is mediated 
by the pVHL E3 ligase. We therefore wanted to understand firstly, if these 
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modified FASN bands represented ubiquitinated forms of FASN; and secondly, 
if the modifications were pVHL dependent. 
 
A de-ubiquitination assay was first conducted using HCT116 F-pVHL cells to 
examine whether the modified FASN bands represent ubiquitinated forms. As 
shown in Figure 3-3 A, under the treatment of USP2a which was reported to 
de-ubiquitinate FASN (Graner, Tang et al. 2004), the modified forms of FASN 
were dramatically reduced (Figure 3-3 A, lane 2) as compared to the 
untreated sample (Figure 3-3 A, lane 1). Upon treatment of the samples with 
both USP2a and ubiquitin aldehyde which is a general 
A B 
Figure 3-3 Examination of ubiquitination of FASN by the pVHL E3 ligase. 
(A) A de-ubiquitination assay in HCT116 F-pVHL cells confirmed that the 
modified FASN bands represent ubiquitinated form. HCT116 cells stably 
expressing Flag-tagged pVHL were treated with 10 μM MG132 overnight 
and lysed for immunoprecipitation using M2 beads. The eluate was used 
for de-ubiquitination assays followed by western blot analysis. (B) VHL 
knockout experiment tested the possibility whether the FASN 
modification was pVHL dependent. The CRISPR/Cas9 knockout method 
was utilized to stably knockout VHL in HCT116 cells, and modified bands 
of FASN were analyzed by western blot analysis. 
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deubiquitinase inhibitor, most of the FASN modified bands were restored 
(Figure 3-3 A, lane 3). This result confirmed that the modified FASN bands 
present in the pVHL complex represent ubiquitinated forms of FASN. 
 
Secondly, VHL knockout experiments using CRISPR/Cas9 method were 
performed to understand whether the FASN modification is pVHL dependent. 
As shown in Figure 3-3 B, pVHL expression was down-regulated to different 
levels as reflected by the HIF-1α stabilization level. As shown in lanes 3 and 4, 
incomplete suppression of pVHL expression by CRISPR/Cas9 method could be 
due to the disruption of only one allele of the gene, which remains to be 
checked by PCR and sequencing. Comparing modified FASN amounts in WT 
cells to those in VHL knockout cells, it can be noticed that slightly less 
modified FASN levels were present in the VHL knockout cells, and this 
response correlates with different pVHL expression levels. However, we never 
notice a dramatic change of the global level of FASN proteins here, indicating 
the function of pVHL to ubiquitinate FASN proteins is rather weak. Moreover, 
pVHL over-expression in pVHL-deficient ccRCC cells failed to increase the 
amount of modified FASN bands (data not shown). Thus we would conclude 
that FASN ubiquitination may not be pVHL dependent. Recently another E3 
ligase named COP1 has been reported to be responsible for FASN 
ubiquitination (Yu, Deng et al. 2013). Thus, it could be possible that COP1 
plays the major role in regulating FASN ubiquitination. 
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Taken together, we showed that FASN is ubiquitinated, but may not be pVHL 
dependent. 
 
• The FASN C-terminal region is important for pVHL-FASN binding, and it 
is ubiquitinated. 
 
Since the physical interaction between pVHL and FASN was validated, we 
wanted to map the specific regions of interaction between pVHL and FASN. 
Flag-tagged full-length FASN as well as N-terminal and C-terminal truncated 
mutants were constructed and transiently transfected into 293T cells to 
determine which region of FASN is responsible for interaction with pVHL. Due 
to the difficulty in detecting endogenous pVHL, a small amount of non-tagged 
pVHL plasmid was co-transfected in all of the samples. As shown in Figure 3-4 
A, all three versions of FASN proteins (i.e. FASN full-length, N-terminal and 
C-terminal proteins) can pull down exogenous pVHL protein (Figure 3-4 A, 
second panel from bottom). Interestingly, FASN C-terminal protein fragments 
pulled down the highest amount of pVHL compared to FASN full-length and 
N-terminal proteins. This indicates that the FASN C-terminal region has higher 
affinity to bind to pVHL. 
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Since we have shown that FASN proteins are ubiquitinated, to understand 
which region of FASN is ubiquitinated, a similar experiment was performed. 
Since the FASN antibody is not able to recognize the C-terminal protein, a Flag 
A B 
Figure 3-4 The FASN C-terminal region is important for pVHL-FASN 
interaction, and it is ubiquitinated. (A) The FASN C-terminal region has 
high affinity to pVHL. 293T cells were transiently transfected with 
Flag-tagged FASN full-length or truncated mutant or control vector, 
respectively. Equal amounts of non-tagged pVHL plasmid were 
co-transfected to all the samples as well. 42 h after transfection, cells 
were then treated with 10 μM MG132 for 6 h. Finally, cells were 
harvested and subjected for immunoprecipitation with M2 beads, and 
used for western blot analysis. (B) The FASN C-terminal region is 
ubiquitinated. 293T cells were transiently transfected with Flag-tagged 
FASN full-length or truncated mutant or control vector, respectively. 36 h 
after transfection, cells were treated with either 10 μM MG132 or 
DMSO for 12 h. Then these cells were harvested and subjected for 
immunoprecipitation with M2 beads, and used for western blot analysis. 
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antibody was used to visualize these FASN proteins. As shown in Figure 3-4 B, 
higher molecular weight bands possibly carrying polyubiquitin were observed 
for the FASN full-length and C-terminal protein pull-down samples, but not in 
the FASN N-terminal protein pull-down samples. This indicates that FASN 
C-terminal region is ubiquitinated. 
 
Taken together, the FASN C-terminal region is ubiquitinated and it mediates 
the interaction with pVHL. 
 
 
• pVHL mutant Y112H loses binding ability to FASN. 
To understand the molecular basis of VHL disease or specificity of pVHL 
mutants in binding to FASN, we utilized seven disease-associated pVHL point 
mutants (W88S, Y112H, H115Q, L158P, R167Q, L184P and R200W, 
respectively), which were selected from the VHL mutations database 
(http://www.umd.be/pVHL/) (Gnarra, Tory et al. 1994; Chen, Kishida et al. 
1995; Olschwang 1999; Hoffman, Ohh et al. 2001; Rathmell, Hickey et al. 
2004). These mutations, as shown in the schematic representation in Figure 
3-5 A, are of relatively high prevalence among 823 mutations reported in VHL 
disease. Flag-tagged pVHL mutants were constructed in lentiviral vectors and 
stably expressed in HCT116 cells, and further subjected to 
immunoprecipitation analysis.  
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The binding activities of these pVHL mutants to the known pVHL interacting 
proteins were first validated, as shown in Figure 3-5 B. According to previous 
studies, the E3 ligase components Elongin C and CUL2 bind to the C-terminal 
A 
B C 
D E 
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region of pVHL (ca. aa157-194) (Iwai, Yamanaka et al. 1999) while HIF-1α 
interacts with central region of pVHL (ca. aa54-158) (Tanimoto, Makino et al. 
2000; Min, Yang et al. 2002). In accordance with these reports, our result 
showed that the pVHL mutants W88S, H115Q, L158P, R167Q lost their ability 
to bind to either HIF-1α or HIF-2α, whereas the mutants L158P, R167Q and 
L184P lost binding to either Elongin C or CUL2. These data are summarized in 
Figure 3-5 E. In Figure 3-5 D, the pVHL complex visualized by silver staining 
showed successful pull down of pVHL-containing complexes, in which Elongin 
C and CUL2 bands were almost completely lost in the complexes of the L158P 
mutant and partially in the case of R167Q and L184P mutants. These results 
were in great agreement with published data and reinforced that loss of 
binding activity to either the E3 ligase components or HIF-α is largely 
Figure 3-5 The pVHL mutant Y112H loses its ability to FASN. (A) 
Schematic representation showing seven analyzed pVHL mutants. (B) 
Binding specificity of pVHL mutants to known pVHL-interacting proteins 
showed that most of the pVHL mutants including W88S, H115Q, L158P, 
R167Q and L184P lost binding activity toward either HIF-1α, HIF-2α, 
Elongin C or CUL2. However, the pVHL mutant Y112H still interacted with 
these proteins. Flag-tagged pVHL mutants were introduced by lentiviral 
vector and stably expressed in HCT116 cells, while plain HCT116 cells and 
HCT116 F-pVHL WT serve as control. After overnight treatment with 10 
μM MG132, cells were lysed for immunoprecipitation with M2 beads. 
Eluates were used for western blot analysis and silver staining. (C) Binding 
specificity of pVHL mutants to newly identified pVHL interacting proteins 
showed that Y112H fail to bind FASN. (D) Components of pull down 
complexes were visualized by silver staining. (E) A summary of the binding 
activity of pVHL mutants to pVHL-interacting proteins. 
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identified in most VHL disease-associated mutants, and might be the major 
cause of disease onset in patients with these mutants. 
 
In contrast, Y112H and R200W still possess the ability to interact with these 
known pVHL-interacting proteins, showing an interaction pattern resembling 
WT pVHL. Thus, it is possible that some unknown mechanism of pVHL may be 
responsible for the onset of disease, and we examined if these novel pVHL 
interacting proteins could provide some molecular insight into these cryptic 
mechanisms. 
 
We analyzed the binding activity of pVHL mutants to our newly identified 
interacting proteins in particular FASN (Figure 3-5 C). It is interesting that 
FASN and CAD showed weaker binding ability to W88S, Y112H and R200W. 
Ubiquitination levels of FASN appeared to correlate with the protein levels. If 
this fact is linked to the previous result that Y112H and R200W can still 
interact with Elongin C, CUL2 or HIF-1α/2α, interaction between pVHL and 
FASN, RNA polymerase II or CAD might be critical to disease onset for patients 
with mutants Y112H and R200W. This reinforces our assumption that some 
unknown regulatory mechanism by other unidentified pVHL interacting 
proteins may be critical for VHL disease onset, and these newly identified 
pVHL interacting proteins may be promising candidates for future studies, to 
explore the molecular details of these cryptic mechanisms. 
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• The pVHL mutant Y112H does not co-localize with FASN and retains the 
function to induce HIF-α degradation. 
As demonstrated in Figure 3-5 C, Y112H loses the binding activity to FASN. 
Thus we further analyzed the cellular localization of this mutant. WT pVHL as 
well as mutants Y112H and H115Q were introduced by lentiviral vector and 
stably expressed in the pVHL deficient ccRCC cell line 786-O cells for 
immunofluorescence staining. As shown in Figure 3-6 A, both WT pVHL and 
H115Q localized in cytoplasm of the cells, while Y112H predominantly 
localized in nucleus of the cells. FASN was retained in cytoplasm for all tested 
cell lines. This nuclear localization of Y112H is consistent with the previous 
finding that Y112H lacks binding activity toward FASN.  
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A 
B 
Figure 3-6 The pVHL mutant Y112H does not co-localize with 
FASN and retains the function to induce HIF-α degradation. 
(A) The pVHL mutant Y112H no longer co-localizes with FASN. 
Immunofluorescence staining was performed using pVHL 
(green fluorescence) and FASN (red fluorescence) antibodies to 
786-O cells stably expressing Flag-tagged WT pVHL as well as 
Flag-tagged pVHL mutants Y112H and H115Q, followed by 
confocal microscopy. (B) The pVHL mutant Y112H retained the 
function to induce HIF-2α degradation. Flag-tagged pVHL 
mutants (W88S, Y112H, H115Q, L158P, R167Q, L184P and 
R200W) were stably expressed in 786-O cells, while parental 
786-O cells and 786-O cells stably expressing Flag-tagged pVHL 
WT serve as control. These cells were treated with 10 μM 
MG132 or DMSO overnight and lysed for western blot analysis. 
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To further examine the function of these pVHL mutants, WT pVHL and seven 
pVHL mutants were introduced by lentiviral vectors and stably expressed in 
786-O cells for western blot analysis. The ability to regulate HIF-2α protein 
levels by these VHL mutants is shown in Figure 3-6 B, left panel (without 
MG132 treatment). pVHL mutants including W88S, H115Q, L158P and L184P 
lost the ability to induce HIF-2α degradation. This could be due to these 
mutants losing their binding abilities to HIF-2α or other E3 ligase components, 
which has been demonstrated in Figure 3-5. In contrast, some pVHL mutants 
including Y112H retained the HIF-2α degradation activity at levels which are 
nearly comparable to WT pVHL. These results are fundamentally consistent 
with previous reports (Rathmell, Hickey et al. 2004; Li, Zhang et al. 2007).  
 
 
3.1.2 FASN regulates HIF-α protein levels depending on pVHL function 
Summary 
The physiological implications of FASN and pVHL interaction are presented in 
this section. FASN knockdown and knockout can lead to decreased HIF-α 
levels as well as downstream targets (Figure 3-7). This correlation between 
FASN and HIF-α protein levels was further shown to be pVHL-dependent but 
independent of FASN catalytic activity (Figure 3-8). FASN can compete with 
other pVHL interacting proteins for the binding with pVHL (Figure 3-9). 
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Contrary to published results with liver-specific conditional knockout mice, 
HIF-α did not affect FASN protein levels in the cancer cells (Figure 3-10), and 
does not constitute a regulatory circuit between these proteins. The possible 
physiological relevance of FASN regulating HIF-α was demonstrated in mouse 
3T3-L1 cells during differentiation to adipocytes, also shown by the inhibiting 
effect of sterol in human cancer cells (Figure 3-11). Furthermore, positive 
correlation of gene expression between FASN and HIF-α targets was observed 
in specimens from prostate cancer patients (Figure 3-12). Therefore our 
findings provided a novel mechanism possibly underlying the oncogenic 
function of FASN through the interaction with pVHL and regulation of HIF-α. 
 
 
• FASN knockdown or knockout leads to HIF-α down-regulation in human 
cancer cells and primary cells.  
 
After confirming the interaction between FASN and pVHL, the next question 
would be to explore the functional significance of this interaction. Since HIF-α 
is a well-characterized substrate of the pVHL E3 ligase complex, we examined 
whether FASN may affect the protein levels of HIF-α. Transient FASN 
knockdown by siRNA in human primary renal epithelial cells (PREC), HeLa and 
HCT116 cells, as well as stable FASN knockout by the CRISPR/Cas9 method in 
HCT116 cells were utilized to test this hypothesis.  
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The results for FASN knockdown by siRNA are shown in Figure 3-7 A. As 
reviewed above, it is well known that the HIF-1α protein is rapidly degraded 
under normoxia (Figure 3-7 A, lane 1, 2, 5, 6, 9 and 10) but stabilized under 
hypoxia (Figure 3-7 A, lane 3, 7 and 11). Interestingly, HIF-1α was no longer 
stabilized by FASN knockdown in all three cell lines under hypoxic conditions 
as shown in Figure 3-7, lanes 4, 8 and 12. This result demonstrated that 
HIF-1α stabilization was compromised by FASN knockdown in hypoxia, in 
human primary cells (PREC) and cancer cells (HeLa and HCT116). Under the 
same experimental settings, HIF-2α also failed to be stabilized by FASN 
knockdown in PREC cells, as shown in Figure 3-7 B. Since HIF-2α is moderately 
Figure 3-7 FASN knockdown or knockout leads to down-regulation of HIF-α 
proteins. (A) HIF-1α stabilization was diminished by FASN knockdown in 
PREC, HeLa and HCT116 cells. FASN siRNA or non-targeting control siRNA 
were transiently transfected to human PREC, HeLa and HCT116 cells. 
Eventually, these cells were harvested in 72 h after transfection. Moreover, 
these transfected cells were cultured in either normoxia or 1 % hypoxia for 4 
h before harvesting. HIF-1α protein levels were determined by western blot 
analysis. (B) Under the same experimental setting as in Figure 3-7 A, HIF-2α 
protein levels were determined by western blot analysis in PREC cells. (C) 
HIF-1α and HIF-2α levels were down-regulated in FASN knockout HCT116 
cells in normoxia. The CRISPR/Cas9 method was utilized to stably knockout 
FASN in HCT116 cells in normoxia. HIF-1α and HIF-2α protein levels were 
determined by western blot analysis. (D) HIF-α regulation by FASN had an 
effect on HIF-α direct downstream target gene expression. Relative mRNA 
levels of eleven HIF-α direct target genes were analyzed by qPCR utilizing 
PREC cells transfected with siRNA targeting FASN and cultured under 1 % 
hypoxia for 24 h. Expression levels were normalized to the mRNA levels of 
the housekeeping gene PPIA, and relative mRNA levels of knockdown 
samples were calculated against the control samples to show the fold 
changes over the control. Data is depicted as the mean ± SD. N=6. Significant 
differences were calculated by Student’s-t test. *P<0.05. 
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expressed under normoxia in PREC cells, FASN-dependent HIF-2α regulation 
was also detected under normoxic conditions. 
 
To reinforce the finding from siRNA knockdown experiments, the CRISPR/Cas9 
strategy was next employed to knockout FASN in HCT116 cells. As shown in 
Figure 3-7 C, FASN proteins were down-regulated to different levels in three 
clones: F3-4, F3-8 and F3-9. Suppression of FASN expression was partial in 
clones F3-4 and F3-8, because F3-4 still has one WT allele and F3-8 has an 
in-frame deletion to produce a protein of near full length as shown from PCR 
and sequencing results (data not shown). Based on different FASN protein 
levels, a positive correlation between FASN and HIF-α protein levels was 
observed. In clone F3-9 carrying frame-shift mutations in both alleles 
(therefore establishing a complete knockout of FASN expression), HIF-1α and 
HIF-2α protein levels appeared to be lower. 
 
To understand the effect of FASN on HIF-α downstream gene expression, 
relative mRNA levels of several HIF-α target genes were analyzed using PREC 
cells, in which FASN was down-regulated by siRNA, and cultured in hypoxia. 
As shown in Figure 3-7 D, most of the analyzed direct HIF-α target genes 
including VEGFA, PGK1, SLC2A1, PDK1, PKM2, CA9, MXI1 and ADM, which are 
important for angiogenesis, metabolism (glycolysis), cell proliferation and 
survival, showed a decreased hypoxic induction response in the FASN 
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knockdown samples. In this way, the potential physiological importance of 
HIF-α regulation by FASN is shown. In addition, the mRNA levels of HIF-1α and 
HIF-2α were also evaluated in this experiment and found to be comparable 
between control and FASN knockdown samples, suggesting that the HIF-α 
regulation by FASN is at the post-translational level. 
 
Taken together, this evidence supported our hypothesis that down-regulation 
of FASN leads to decreased HIF-1α and HIF-2α protein levels, and thereby 
regulates HIF-α downstream target genes controlling various cellular 
physiological processes. 
 
 
• Regulation of HIF-α by FASN requires the presence of pVHL; however, 
the catalytic activity of FASN may not be important for this effect. 
Since we found that pVHL interacts with FASN and there was a positive 
correlation between FASN and HIF-α protein levels, we next tested whether 
regulation of HIF-α levels and function by FASN is pVHL-dependent. The 
involvement of the FASN enzymatic activity in this mode of HIF-α regulation 
was also tested.  
 
Firstly, SKRC10 and SKRC10 F-pVHL cells were used to examine if the HIF-α 
regulation by FASN is pVHL-dependent. SKRC10 is a pVHL-deficient ccRCC cell 
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line. F-pVHL was introduced in the parental cells by lentiviral vectors to 
establish the SKRC10 F-pVHL cells. As shown in Figure 3-8 A, in SKRC10 cells 
that do not express functional pVHL, HIF-1α and HIF-2α were constitutively 
stabilized in both normoxia and hypoxia (Figure 3-8 A, lane 1 and 3). 
Knockdown of FASN expression did not lead to any changes in HIF-1α or 
HIF-2α levels (Figure 3-8 A, lane 2 and 4). This result indicates that FASN 
cannot regulate HIF-α without functional pVHL. This was also confirmed in 
other pVHL-deficient ccRCC cell lines, 786-O and A498, by showing that 
HIF-2α is not responsive to FASN knockdown (Figure 3-8 B). These two cell 
lines express HIF-2α but not HIF-1α, thus only HIF-2α was analyzed in this 
experiment. On the contrary, in the presence of functional pVHL, a decrease 
in HIF-1α and HIF-2α levels was detected upon knockdown of FASN 
expression. As shown in SKRC10 F-pVHL cells, both HIF-1α and HIF-2α were 
degraded in normoxia (Figure 3-8 A, lane 5 and 6) and stabilized in hypoxia 
(Figure 3-8 A, lane 7), but suppressed by FASN knockdown in the presence of 
exogenous pVHL (Figure 3-8 A, lane 8). This result suggests that HIF-α 
regulation by FASN requires functional pVHL.  
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Next, we took advantage of the pVHL mutant Y112H to further confirm that 
A B 
C 
Figure 3-8 Regulation of HIF-α by FASN requires the presence of WT pVHL. 
(A) Down-regulation of HIF-1α and HIF-2α levels by knockdown of FASN can 
only be achieved in pVHL expressing cells, but not in pVHL-deficient cells or 
pVHL Y112H-expressing cells. Flag-tagged pVHL WT and mutant Y112H 
were stably expressed in the pVHL-deficient SKRC10 cells, which express a 
moderate level of HIF-1α and HIF-2α. Stable cells and parental cells were 
transfected with FASN siRNA and non-targeting control siRNA, cultured in 
either normoxia or 0.1 % hypoxia for 4 h before harvested for western blot 
analysis. Hypoxia at a lower oxygen level (0.1 %) was set in this experiment 
since exogenous pVHL driven even by a weaker promoter possesses a 
potent ability to degrade HIF-α under 1 % hypoxia. Thus 0.1 % hypoxia was 
used to circumvent this situation. (B) HIF-2α levels were not altered upon 
FASN knockdown in pVHL-deficient cells. pVHL-deficient 786-O and A498 
cells, which express HIF-2α but not HIF-1α, were transfected with FASN 
siRNA or non-targeting control siRNA, cultured in either normoxia or 1 % 
hypoxia for 4 h and then harvested for western blot analysis. (C) Catalytic 
activity of FASN was shown to be not important for regulation of HIF-α. 
PREC, HeLa and HCT116 cells were cultured in normoxia or 1 % hypoxia for 
4 h and treated with 0, 25 or 50 μM of the FASN enzymatic inhibitor 
Cerulenin for 4 h, and harvested for western blot analysis. 
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the interaction between FASN and WT pVHL is required for regulation of 
HIF-α by FASN. Re-introduction of Y112H pVHL in SKRC10 cells restored HIF-α 
suppression in normoxia (Figure 3-8 A, lanes 9 and 10). However, unlike cells 
expressing the WT pVHL, HIF-1α and HIF-2α did not show any changes upon 
knockdown of FASN expression (Figure 3-8 A, lane 11 and 12). In conclusion, 
we show that Y112H cannot restore the HIF-α suppression following FASN 
knockdown, which is in unison with our results that Y112H does not bind to 
FASN (Figure 3-5 C) and no longer co-localizes with FASN in HCT116 and HeLa 
cells (Figure 3-6 A). This result emphasizes that the interaction between FASN 
and WT pVHL is required for the FASN-HIF-α regulation. 
 
We also tested whether regulation of HIF-α depends on the catalytic activity 
of FASN by treating PREC, HeLa and HCT116 cells with the FASN enzymatic 
inhibitor Cerulenin. As shown in Figure 3-8 C, the results suggested that 
increased Cerulenin dosage did not affect HIF-1α protein levels. Thus, it 
appears that the catalytic activity of FASN is not required for HIF-α regulation. 
 
Taken together, our data suggests that pVHL interaction with FASN is critical 
for HIF-α regulation, which prompted us to analyze the composition of 
pVHL-containing complexes in the subsequent studies. 
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• FASN competes with other pVHL interacting proteins and binds to pVHL.  
Since we have shown that FASN regulates HIF-α levels depending on pVHL 
function, we suggested a model herein that FASN may compete with HIF-α or 
other pVHL E3 ligase components for binding to pVHL. To test this hypothesis, 
a transient transfection experiment was performed in 293T cells to examine if 
there is any competition between FASN and other pVHL interacting proteins.  
 
As shown in Figure 3-9 lane 6, HIF-1α, FASN as well as the pVHL E3 ligase 
components CUL2 and Elongin C were co-precipitated by F-pVHL. However, as 
shown in Figure 3-9 lane 8, following pull-down of Flag-tagged FASN (F-FASN) 
complexes, neither CUL2 nor Elongin C were precipitated, whereas pVHL was 
readily detected. This result suggests that the interaction between FASN and 
pVHL can interfere with the binding between pVHL and other E3 ligase 
components as well as HIF-1α. Here we have provided a pVHL-dependent 
mechanism for HIF-α regulation by FASN, which will be further discussed 
below. 
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• Both HIF-1α and HIF-2α do not regulate FASN protein levels in human 
and mouse primary cells as well as human colon cancer and liver cancer 
cell lines. 
As reviewed above, there is a report indicating that HIF-2α might have a 
Figure 3-9 FASN competes with other pVHL 
interacting proteins and binds to pVHL. Equal 
amounts of FASN or Flag-tagged FASN, pVHL or 
Flag-tagged pVHL were transiently expressed in 
293T cells respectively together with HA-tagged 
HIF-1α. HIF-1α was co-transfected since it is 
barely expressed in 293T cells. Cells were 
treated with 10 μM MG132 overnight before 
harvesting. 48 h after transfection, cells were 
harvested and the lysates were subjected to 
immunoprecipitation with M2 beads. Eluates 
were analyzed by western blot analysis. 
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negative regulatory effect on FASN mRNA levels in a mouse model (Rankin, 
A 
B 
C 
Figure 3-10 Both HIF-1α and HIF-2α do not regulate FASN protein levels in 
human and mouse primary cells as well as human colon cancer and liver 
cancer cell. (A) Up-regulation of HIF-α protein levels by DFO did not affect 
FASN protein levels in human primary and cancer cells. PREC and HCT116 cells 
as well as human liver cancer cell line HepG2 were treated with DMSO or 
different dosages of DFO for 12 h and harvested for western blot analysis. (B) 
HIF-α protein up-regulation induced by hypoxia did not affect the FASN 
protein levels in mouse primary liver cells. Mouse primary liver cells were 
cultured in normoxia or 1 % hypoxia for 24 h or 48 h, and the cells were 
harvested for western blot analysis. (C) Stably over-expressed exogenous 
HIF-α did not affect FASN protein levels. HIF-1α or HIF-2α was stably 
expressed in HCT116 and HepG2 cells by lentiviral vectors and different 
clones as well as the parental cells were harvested for western blot analysis. 
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Rha et al. 2009). Since we have shown that FASN can positively regulate HIF-α 
protein levels, we examined the possibility if HIF-α may regulate FASN protein 
levels in our experimental system. As shown in Figure 3-10, firstly, HIF-1α and 
HIF-2α protein levels were up-regulated by treatment with the Fe2+ chelator 
Desferrioxamine (DFO) which has been widely used to stabilize HIF-α proteins 
(Wang and Semenza 1993) in HCT116 and HepG2 (human liver cancer) cells 
(Figure 3-10 A). Protein expression levels of the HIF-α target REDD1 were also 
up-regulated. However, we did not observe any change in FASN protein levels. 
Moreover, although HIF-1α protein was up-regulated by hypoxia in primary 
mouse liver cells (Figure 3-10 B), no change in FASN expression levels was 
observed. In addition, similar results were obtained with HCT116 and HepG2 
cells stably over-expressing HIF-1α or HIF-2α (Figure 3-10 C). The discrepancy 
between our observations and those by Haase might be due to the different 
experimental systems used. In Haase’s study, the results were obtained from 
liver tissues of HIF-α conditional knockout mouse model, which reflects the in 
vivo situation and may represent a long-term regulatory relationship between 
HIF-α and FASN. Our experiments were conducted using human cancer cell 
lines and mouse cell lines under cell culture conditions, and represent a 
short-term regulatory relationship between HIF-α and FASN. In summary, we 
did not observe any changes of FASN protein expression levels by 
up-regulation of HIF-α proteins, suggesting that the HIF-α signaling pathway 
does not regulate FASN protein levels under our experimental conditions. 
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• Up-regulation of FASN during 3T3-L1 cell differentiation into adipocytes 
is accompanied by HIF-α stabilization and activation of the HIF-α target 
gene REDD1. Moreover, sterol has an inhibiting effect on HIF-α 
regulation in human cancer cells. 
To investigate the physiological relevance of HIF-α regulation by FASN, we first 
utilized a well-established experimental system to induce FASN expression in 
3T3-L1 cells (Kim and Spiegelman 1996). 
 
Differentiation of 3T3-L1 into adipocyte-like cells can be induced by 
administration of insulin, dexamethasone, and 3-isobutyl-1-methylxanthine 
(IBMX). This will further lead to increase in FASN protein production and lipid 
synthesis, which can be monitored by staining with Oil Red O. As shown in 
Figure 3-11 A panel 1, no staining was observed without induction of 
differentiation, showing that no lipid synthesis was induced. Conversely, cells 
cultured in differentiation medium-1 (panel 2) or differentiation medium-2 
(panel 3) exhibited weak or strong Oil Red O staining. Thus, lipid synthesis 
was stimulated under these conditions. 
 
In accordance with the Oil Red O staining result, FASN protein was induced to 
different levels. As expected, HIF-1α and HIF-2α as well as one of the targets 
REDD1 were up-regulated correspondingly with the FASN protein levels 
(Figure 3-11 B). This result again confirmed that FASN up-regulation leads to 
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stabilization of HIF-α and induction of HIF-α target gene expression. 
Figure 3-11 FASN up-regulation during 3T3-L1 differentiation into adipocytes is 
accompanied with stabilization of HIF-α and activation of the HIF-α target 
REDD1; sterol has an inhibiting effect on HIF-α levels in human cancer cells. (A) 
Oil Red O staining shows that differentiation of 3T3-L1 cells is successfully 
induced. 3T3-L1 cells were cultured in normal medium as well as differentiation 
medium-1 or differentiation medium-2 for 20 days to induce up-regulation of 
FASN and lipid synthesis. Cells were then fixed with 10 % formaldehyde in PBS 
and stained with Oil Red O. (B) HIF-α levels as well as the downstream target 
REDD1 were induced by FASN up-regulation under these physiological 
conditions. Cells were cultured under exactly the same conditions as in Figure 
3-11 A and harvested for western blot analysis. (C) Sterol had an inhibiting effect 
on HIF-α levels. HCT116, HeLa and 293T cells were treated with 
25-hydroxycholesterol at 0, 0.5 or 2 μg/ml for 72 h and cultured in 1 % hypoxic 
condition for 4 h, then subjected for western blot analysis. 
 
A 
B C 
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In addition, we tested sterol effect in HCT116, HeLa and 293T cells to 
understand if HIF-α protein levels are affected by upstream signaling 
regulating FASN expression levels. 
 
As reviewed above, the transcription factor SREBP1 can induce FASN gene 
expression (Kim and Spiegelman 1996), and the extracellular sterol status is 
an important regulator of SREBP1 function (Wang, Sato et al. 1994). Brown 
and Goldstein showed that when sterol is depleted, the N-terminal region of 
SREBP1 is cleaved and translocates into the nucleus to function as a 
transcription factor; while excessive sterol inhibits this process (Wang, Sato et 
al. 1994). Taking advantage of this knowledge, we tested the effect of sterol 
on regulation of HIF-α levels by FASN. Our results showed that excessive 
sterol inhibited mature SREBP1 and FASN protein levels, and under hypoxic 
conditions, led to HIF-α down-regulation in these three cell lines. As shown in 
Figure 3-11 C, cells treated with higher dosage of 25-hydroxycholesterol 
showed lower FASN protein levels, as well as lower HIF-α protein levels. 
Importantly, this observation suggests a new possibility that upstream 
regulators of FASN such as SREBP1 and sterols may physiologically regulate 
HIF-α and downstream target genes. Since some studies have shown the 
anti-tumor effect of 25-hydroxycholesterol inducing apoptosis in human 
Leukemic cells (Ayala-Torres, Moller et al. 1997), it is conceivable that these 
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sterol compounds can serve as potential HIF-α inhibitors for translational 
research. 
 
 
• FASN levels correlate with HIF-α target gene levels in prostate cancer 
patients, especially in the metastatic stage. 
To understand the clinical significance of the relationship between FASN and 
HIF-α, mRNA levels of FASN and HIF-α target genes were analyzed using gene 
expression profiles obtained from prostate cancer patient samples. 
 
The analysis was performed using the IST Online (Medisapiens) database that 
contains gene expression data on both cancer and normal samples. A 
prostate cancer dataset containing the information of about 220 patients was 
examined to determine how increased FASN expression corresponds with the 
hypoxia status in different subtypes as indicated by the up-regulation of 
classical HIF-α targets including VEGFA, ADM, PDK1, HK2, DDIT4, KDM3A and 
MXI1. Indeed, all of these HIF-α target genes were found to have increased 
expression levels that clusters with high FASN levels as shown in red color in 
the heat map (Figure 3-12). Moreover, FASN and HIF-α targets showed very 
high correlation particularly in aggressive metastasis prostate cancer samples, 
as shown in black in the M staging information (Figure 3-12). This result 
indicates that FASN correlates with HIF-α target gene expression levels 
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especially in prostate cancer patients in the metastatic stage. It also indicates 
that the correlation between FASN and HIF-α might serve as a potential 
prognosis marker for these patients. 
 
Summary 
In summary, we have shown that pVHL interacts with FASN, and this 
interaction was shown to regulate HIF-α protein levels in both a physiological 
and cancer context. Further discussion on these results would be found in the 
next section. 
 
  
Figure 3-12 FASN levels correlate with HIF-α target gene expression levels 
in prostate cancer patients, especially patients in the metastatic stage. The 
gene expression from public database IST Online (Medisapiens) was 
analyzed, and mRNA levels of several HIF-α target genes were aligned 
according to the FASN levels. Expression levels were indicated in the color 
bar as red for up-regulation and blue for down-regulation. M Staging was 
used for the evaluation of distant metastasis, where white, black and gray 
indicates the M0 stage, M1 stage and no data, respectively. 
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3.2 Discussion  
3.2.1 Important findings and discussion  
This study for the first time demonstrated regulation of HIF-1α and HIF-2α 
through pVHL-FASN interaction, and has given indications regarding the 
physiological significance of this interaction. These findings will be discussed 
under two sections: physical interaction between pVHL and FASN, and FASN 
regulation of HIF-α protein levels depending on pVHL function under several 
physiological or pathophysiological conditions. 
 
• Physical interaction between pVHL and FASN 
In our study, FASN was identified as a novel pVHL interacting protein. So 
far there are only three publications reporting on protein interaction with 
FASN. By analyzing USP2a protein complexes using pull down and mass 
spectrometry analysis, Loda and colleagues found an interaction between 
FASN and USP2a, and showed that USP2a can remove the ubiquitin froms 
ubiquitinated form of FASN in human prostate cancer cells (LNCaP) 
(Graner, Tang et al. 2004). Feng and colleagues detected FASN in the 
SH2-Tyrosine Phosphatase (Shp2) protein complex, and showed that the 
E3 ligase COP1 regulates the degradation of FASN probably through Shp2 
mediation in 293T cells (Yu, Deng et al. 2013). Cheng and colleagues 
identified FASN a protein interacting with the Hepatitis C virus (HCV) 
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nonstructural protein 5B (NS5B) in a pull down screening assay and 
showed that this interaction can modulate HCV replication in 
HCV-permissive Huh7 hepatoma cells (Huang, Tseng et al. 2013). The 
latter was reported to apparently represent an enzymatic 
activity-independent function of FASN. Our study presents another 
enzymatic activity-independent function of FASN in regulating HIF-α levels 
and function, by the interaction between pVHL and FASN. 
 
• FASN regulating HIF-α protein levels, depending on pVHL function 
Haase and colleagues reported neutral lipid accumulation in Vhl-deficient 
mice liver, observing the lipid vacuoles in these livers by Oil Red O staining 
(Haase, Glickman et al. 2001; Rankin, Rha et al. 2009). In addition, lipid 
accumulation was found in neoplastic stomal cells in pVHL-accociated 
hemangioblastomas (Kim and Kaelin 2004). Interestingly, these 
observations indicate a potential relationship between FASN and HIF-α. To 
assess the physiological importance of FASN and pVHL interaction, we 
discovered for the first time that HIF-α protein levels were positively 
regulated by FASN, and further proved that this regulation is 
pVHL-dependent. From a mechanistic point of view, FASN might occupy 
pVHL and compete with other pVHL interacting proteins for pVHL, 
impairing the integrity of the E3 ligase complex and preventing HIF-α 
degradation (Figure 3-13, Figure 3-9).  
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Another remarkable finding is that the pVHL mutant Y112H lost binding 
activity to FASN, which may provide a mechanism for HIF-α degradation 
by Y112H (Figure 3-14, Figure 3-6). Kaelin and colleagues pointed out that 
Y112H cannot fully restore the ability to suppress HIF-α, thus HIF-α 
proteins may still play an important role in tumorigenesis (Li, Zhang et al. 
2007). Therefore it is possible that the tumorigenic activity of Y112H is 
HIF-α-dependent, which still remains to be investigated. 
 
Figure 3-13 Diagram showing the mechanism of HIF-α 
regulation by FASN via pVHL. FASN may occupy pVHL and 
compete with other pVHL interacting proteins to bind to 
pVHL, impairing the integrity of E3 ligase complex and thus 
preventing HIF-α degradation. 
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In regard to potential physiological consequences of HIF-α regulation by 
FASN, we showed that this interaction affected expression in hypoxia of 
HIF-α direct downstream target genes in mouse 3T3-L1 cells, human PREC 
cells as well as prostate cancer patient samples. These analyzed HIF-α 
direct target genes included VEGFA, PGK1, SLC2A1, PDK1, PKM2, CA9, 
MXI1 and REDD1, represent important regulators of angiogenesis, 
metabolism (glycolysis), cell proliferation and cell survival (Tsuzuki, 
Fukumura et al. 2000; Kim, Tchernyshyov et al. 2006; Zhang, Gao et al. 
2007; Luo, Hu et al. 2011). PKM2 is a key enzyme within glycolysis, and 
one of the major target genes of HIF-α. Interestingly, PKM2 was shown to 
act as an activator of HIF-1α in conjunction with PHD3. Therefore, this 
Figure 3-14 Diagram showing the 
mechanism of how pVHL mutant 
Y112H leads to HIF-α degradation. 
Y112H loses the binding activity to 
FASN, thus HIF-α cannot be stabilized 
by FASN in this case. 
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constitutes a positive regulatory loop of HIF-α-regulated transcriptional 
activation of PKM2 and concomitantly enhancing other HIF-α target genes 
(Luo, Hu et al. 2011).  
 
Haase and colleagues showed that FASN mRNA levels were lower in liver 
tissues of liver-specific conditional Vhl knockout mice which have higher 
HIF-1α and HIF-2α expression levels, and that this mode of repression of 
FASN expression was reversed by further disruption of the HIF-2a but not 
the HIF-1a locus (Rankin, Rha et al. 2009), linking HIF-2α to FASN 
repression. These observations, in combination with our findings that 
HIF-α protein levels can be regulated by FASN, suggest that there might be 
a negative feedback regulation between FASN and HIF-2α. However, this 
possible mode of feedback-loop of regulation remains to be investigated 
in closer detail. The interaction between FASN and CAD indicates a model 
of functional protein complexes containing two important metabolic 
enzymes, which is also a very interesting aspect, which requires 
investigation in the future. Moreover, there are several well-known 
upstream regulators of FASN. As reviewed above, SREBP1 can regulate 
FASN expression at the transcriptional level (Kim and Spiegelman 1996; 
Rawson 2003; Eberle, Hegarty et al. 2004), and this regulation by SREBP1 
is induced by sterol depletion (Wang, Sato et al. 1994). In our study, we 
show that sterol can serve as an upstream signal to inhibit HIF-α (Figure 
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3-11). This finding definitely indicates another layer of HIF-α regulation. 
FASN functioning as an upstream regulator of HIF-α opens up the 
possibility that both metabolites and a metabolic enzyme can conduct 
fine-tuning of regulation of HIF-α and various downstream genes. Indeed, 
taken together, the FASN and HIF-α relationship is suggesting a complex 
network among different signaling and metabolic pathways (Figure 3-15), 
which would be very crucial for cancer cells to sense the 
microenvironment stimuli and take advantage of these for survival. 
 
Regarding its clinical significance, FASN has been reported to be 
up-regulated in many cancer types. In particular, there is strong evidence 
of FASN being a bona fide oncogene in prostate cancer. Human prostate 
epithelial cells (iPrECs) and human prostate cancer cells (LNCaP) 
expressing ectopic FASN show accelerated cell proliferation and an 
increased growth rate in soft agar, and form an invasive tumor mass in 
xenograft experiments; moreover, tumor have been detected in the 
prostate of FASN-expressing transgenic mice (Migita, Ruiz et al. 2009). 
However, so far it is still poorly understood why and how cancer cells can 
take advantage of this up-regulation of FASN. Our results indicate that 
HIF-α may be the critical factor contributing to the survival and 
proliferation of cancer cells with up-regulation of FASN. Our meta-analysis 
study of clinical data strongly indicates the correlation between FASN and 
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HIF-α target genes in prostate cancer, reinforcing our hypothesis. This 
correlation between FASN and HIF-α target gene expression is suggested 
by another study: xenograft samples using human breast cancer cell lines 
as well as tissue specimen from breast cancer patients were stained with 
antibodies against FASN and CA9 (a HIF-α direct target), and these two 
proteins were concomitantly detected at a high score in most of the cases 
(Furuta, Pai et al. 2008). To summarize, our study reveals a possibility that 
cancer cells with up-regulation of FASN could gain an oncogenic 
advantage through activating HIF-α and its downstream pathways. 
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Figure 3-15 Diagram showing the pathways involved in the 
FASN-pVHL-HIF-α regulatory pathway. In the present study, we have 
shown that FASN can sequester pVHL and thus result in stabilization of 
HIF-α and induction of HIF-α downstream targets regulating e.g. 
metabolism, cell proliferation and angiogenesis. Sterols, which are 
signaling upstream of FASN via SREBP1, have an inhibiting effect on 
HIF-α proteins. FASN and CAD can form a metabolic protein complex, 
which remains to be studied. FASN and CAD may form a regulatory 
loop with HIF-α, which also remains to be studied. Semenza and 
colleagues have previously reported the feed-forward loop between 
PKM2 and HIF-α. This FASN-pVHL-HIF-α relationship builds up a 
complex network between hypoxia, fatty acid synthesis, pyrimidine 
synthesis and glycolysis. It also suggests a relationship between 
oncogenic pathways (oncogenes and/or tumor suppressors) and 
metabolic pathways (metabolic enzymes and/or metabolites). In this 
diagram, blue arrows represent induction, red arrows represent 
repression, and dotted arrows represent a potential regulation.  
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3.2.2 Limitations of the current study and suggestions for the future 
work 
Regarding the FASN-HIF-α regulatory mechanism, it would be interesting to 
elucidate the signaling pathways upstream of FASN all the way to 
downstream of HIF-α. To further understand the upstream pathways, more 
evidence of the sterol effect on FASN and HIF-α levels needs to be provided. 
For example, the sterol effect should be tested on FASN knockout cells to 
validate FASN-dependency. Mouse models would be powerful tools to further 
understand the downstream pathways. For example, human cancer cells 
stably expressing ectopic FASN will be used for xenograft experiments and 
tumors will be used for analyzing the HIF-α proteins and HIF-α downstream 
target gene expression. 
 
Since sterols have an inhibiting effect on HIF-α levels and function as shown in 
our study, sterols and other similar chemical compounds could be considered 
as alternative HIF-α inhibitors in cancer therapy. Speculating on its possible 
translational application, multi-drug treatment with sterol compounds 
together with other HIF-α inhibitors, for instance, target tumor angiogenesis. 
 
Summary 
In summary, we have provided evidence demonstrating the physical 
interaction between FASN and pVHL, and the physiological significance of this 
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interaction would be regulation of HIF-α protein levels. Limitations and 
recommendation for future work were considered regarding further pathway 
studies and potential studies on drug effect. Overall, this work provides a 
deeper understanding of FASN-pVHL-HIF-α associated tumorigenesis, and 
may further provide insights into the mechanism of cancer therapies 
targeting FASN. 
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Chapter 4 UTX-pVHL combinational effect on 
preventing tumorigenesis 
 
4.1 Results 
As reviewed in the introduction, an important question remains if that ccRCC 
development requires mechanisms in addition to loss of function of pVHL, e.g. 
additional co-mutational events (Mandriota, Turner et al. 2002; Kapitsinou 
and Haase 2008). Interestingly, mutations of several genes have been 
identified in ccRCC, including UTX, SETD2, PBRM1 and several mTOR 
pathway-related genes (van Haaften, Dalgliesh et al. 2009; Dalgliesh, Furge et 
al. 2010). It would be expected that co-mutated genes might have 
cooperative or complementary functions to induce fully malignant 
phenotypes. In this part of our study, the function of UTX as a potential tumor 
suppressor was investigated; in particular we examined its ability to 
cooperate with pVHL in regulating the anchorage-independent cell growth 
ability, and investigated possible underlying molecular mechanisms. 
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4.1.1 UTX-VHL loss-of-function leads to increased 
anchorage-independent cell growth ability 
 
• Utx-Vhl loss-of-function provides MEF cells with increased 
anchorage-independent cell growth ability.  
As reviewed in the introduction, Dalgliesh and colleagues identified UTX 
mutations in 5 out of 101 ccRCC patients. Interestingly, 2 out of 5 UTX 
mutations were found co-mutated with VHL (Dalgliesh, Furge et al. 2010). To 
examine the relevance of UTX-VHL co-mutations in a cell culture system, in 
B A 
Figure 4-1 Utx-Vhl loss-of-function provides MEF cells with increased 
anchorage-independent cell growth ability. (A) Utx and Vhl were 
down-regulated concurrently in transformed flox-Vhl MEF cells. The flox-Vhl 
MEF cells were originally obtained from flox-Vhl mouse embryos, and 
transformed with SV40 Large T-antigen. The cells were infected with Adeno 
Cre virus in order to establish Vhl-KO cells. Lentivirus expressing control or 
shRNA (sh-Utx1 or sh-Utx4) was delivered to the Vhl-KO cells, to obtain 
Vhl-KO+Utx-KD cells. Stable cells were harvested for western blot analysis. 
(B) Vhl-KO+Utx-KD cells show stronger tumorigenic potential. Utilizing the 
same cell lines as shown in Figure 4-1 A, soft agar assays were conducted 
testing the anchorage-independent colony formation activity of these cells. 
Average colony numbers of triplicates are presented in bar chart. Data is 
depicted as the mean + SD. N=3.  
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vitro anchorage-independent cell growth activities were tested using 
transformed mouse embryonic fibroblasts (MEFs) with concurrent Vhl 
knockout and Utx knockdown (hereafter referred to as Vhl-KO+Utx-KD) in soft 
agar colony formation assays. The anchorage-independent cell growth activity 
is considered as an in vitro property of potential tumorigenic ability of the 
cells (Freedman and Shin 1974). In these MEF cells the Vhl alleles were 
modified by inserting the first exon between two loxA sequences, and the 
first exon was excised by infecting these cells with adenovirus expressing Cre 
recombinase (Haase, Glickman et al. 2001; Lei, Mason et al. 2008). Utx 
expression was down-regulated by stably expressing shRNA through lentiviral 
vector infection. We confirmed deletion of Vhl by Cre and knockdown of UTX 
expression by shRNA through western blot analysis (Figure 4-1 A). Soft agar 
colony formation assays show that cells deficient in both Utx and Vhl proteins 
can form bigger and higher number of colonies, indicating enhanced 
anchorage-independent cell growth ability compared to the control cells 
(Figure 4-1 B and C). This result would indicate the possibility that UTX-VHL 
co-mutations could be one possible cause to fully induce tumorigenesis. Here 
we noticed that MEF cells with Vhl disruption alone exhibit mild effect on 
anchorage-independent colony formation activity (Figure 4-1 B, top panel), 
indicating that UTX itself may have a potent tumor suppressor function.  
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• UTX knockdown in pVHL-deficient ccRCC cells enhances 
anchorage-independent cell growth ability.  
To further investigate the potential tumorigenic ability of UTX-VHL 
co-mutations in human cancer cell lines, pVHL-deficient ccRCC cell lines were 
utilized for UTX knockdown to mimic the UTX-VHL co-mutation status in 
ccRCC.  
 
As shown in Figure 4-2 A, the pVHL-deficient cell line 786-O was chosen since 
it has moderate UTX expression levels (Figure 4-2 A). Through stable 
knockdown with two kinds of shRNA, both clones showed low UTX expressing 
levels (Figure 4-2 B). Soft agar colony formation assays were then performed 
with one shRNA knockdown clone. As shown in Figure 4-2 C, the 786-O cells 
with decreased UTX levels showed spreading cell morphology on a cell 
culture dish (Figure 4-2 C, top panel) as well as bigger colonies with dispersed 
colony morphology in soft agar assays (Figure 4-2 C, bottom panel). This 
preliminary result suggests that UTX knockdown in pVHL-deficient ccRCC cells 
leads to enhanced anchorage-independent cell growth ability, which provided 
more evidence for the possibility that UTX-VHL co-mutations might function 
in a concert manner to induce tumorigenesis, which remains to be further 
confirmed using mouse xenograft experiments. 
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4.1.2 Analysis of combinational effects of Utx-Vhl loss-of-function on 
gene expression 
 
• Several cancer-related pathways are dysregulated in Vhl-KO+Utx-KD 
MEF cells. 
To investigate the molecular mechanisms underlying an enhanced 
anchorage-independent cell growth activity by UTX-VHL co-mutations, gene 
A B 
Figure 4-2 UTX knockdown in pVHL-deficient ccRCC cells enhances 
anchorage-independent cell growth ability. (A) pVHL-deficient 
786-O cells were used to perform UTX knockdown. Several human 
cancer cell lines including HeLa (Cervical cancer), HCT116 (Colon 
cancer), 786-O, SKRC10, SKRC17, SKRC21 and A498 (ccRCC, pVHL 
deficient), PC3 (786-O sub-line), PV6 (PC3 expressing exogenous 
pVHL) were screened by western blot analysis to analyze for UTX 
expression levels. (B) UTX was stably knocked down using sh-UTX3 
and sh-UTX4 as well as control lentivirus in pVHL-deficient 786-O 
cells, and harvested for western blot analysis. (C) 786-O cells with 
decreased UTX levels showed cell morphology changes and 
presented enhanced colony formation activity. UTX knockdown cells 
(sh-UTX3) as well as control cells were analyzed by soft agar assays. 
 
C 
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profile and pathway analyses were conducted using Utx knockdown cells and 
Vhl-KO+Utx-KD cells. 
 
A B 
C 
D 
Figure 4-3 Several cancer-related pathways are dysregulated in Utx 
knockdown and Vhl-KO+Utx-KD MEF cells. (A) (B) Gene profile analysis 
showed that hundreds of genes were dysregulated in Utx knockdown and 
Vhl-KO+Utx-KD MEF cells. Microarray analysis was conducted using Utx 
knockdown MEF cells as well as Vhl-KO+Utx-KD MEF cells, which have been 
described in Figure 4-1. (C) Pathway analysis identified the top five 
dysregulated pathways in the Vhl-KO+Utx-KD cells. Gene ontology analysis was 
conducted by inputting the gene list containing all the dysregulated gene 
names and values into the IPA software. (D) A number of possible downstream 
targets were validated by qPCR analysis. Data is depicted as the mean + SD. 
N=3. 
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By comparing the gene expression profiles of these knockdown cells to that of 
control cells, nearly 350 genes were found to be significantly up-regulated (in 
red) or down-regulated (in green) to over 1.5 fold changes (Figure 4-3 A and 
B). The identities of dysregulated genes and total gene numbers showed 
variation between Vhl-KO+Utx-KD samples and Utx knockdown samples, 
demonstrating that UTX has its own specific downstream targets. The 
UTX-VHL knockdown combination could also regulate some specific 
downstream targets. Moreover, gene ontology analysis identified the top five 
significantly regulated functional gene categories, including cellular 
movement, cellular growth and proliferation, cellular development, 
cell-to-cell signaling and interaction, cell death and survival (Figure 4-3 C). All 
these categories are functionally closely related to tumorigenic events. Next, 
by further looking into these five categories, we selected several 
cancer-associated downstream genes, including FOXQ1, RAGB, RAGD, 
ATP6AP2, for validation by qPCR analysis (Figure 4-3 D). Among them, RAGB 
and RAGD are known as upstream regulators of mTOR pathway 
(Shimobayashi and Hall 2014), indicating that the Utx-Vhl loss-of-function 
might trigger the activation of mTOR pathways, which remains to be further 
elucidated. Taken together, these changes in target gene expression provide 
information to possibly explain the potential tumorigenic abilities of 
Vhl-KO+Utx-KD MEF cells, which might lead to understanding why VHL and 
UTX are co-mutated in the ccRCC setting. 
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4.1.3 Potential tumor suppressor function of UTX  
• Exogenous UTX expression in HeLa cells results in reduced 
anchorage-independent cell growth ability. Utx knockdown leads to 
increased anchorage-independent cell growth activity of MEF cells, 
which can be rescued by UTX complementation. 
So far we showed that UTX-VHL loss-of-function can induce 
anchorage-independent cell growth activity in MEF and ccRCC cells, and 
changes in expression of several candidate genes may possibly account for 
this ability. Accumulating evidence indicates that UTX can play an important 
role as a potential tumor suppressor independently of pVHL. This possibility 
was tested in the next step. 
 
Firstly, as shown in Figure 4-4, exogenous UTX was stably expressed in HeLa 
cells and the tumorigenic activity was examined by soft agar assays. The 
results showed that UTX up-regulation leads to weaker colony forming activity. 
This indicates that cells with higher UTX expression levels possess weaker 
colony forming ability compared to control cells (Figure 4-4 B). HeLa cells 
were used since they express UTX proteins at low levels, as shown in Figure 
4-4 A.  
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In addition, expression of mouse Utx stably knocked-down in transformed 
MEF cells (Figure 4-5 A, left) was stably rescued with human UTX protein 
(Figure 4-5 A, right). Anchorage-independent cell growth activities were 
tested by soft agar and spheroid formation assays. The results showed that 
Utx knockdown cells gained a stronger ability to form colonies in soft agar 
assays (Figure 4-5 B, top panel), whereas this activity was repressed when 
UTX was introduced to these knockdown cells (Figure 4-5 B, bottom panel). 
The results from spheroid assays were consistent with that from soft agar 
assays (Figure 4-5 C). These observations suggest the important role of UTX 
itself as a potential tumor repressor. 
A B 
Figure 4-4 Exogenous UTX expression in HeLa cells results in reduced 
anchorage-independent cell growth activity. (A) Expression of 
exogenous UTX in HeLa F-UTX cells and control cells. Exogenous UTX 
was stably expressed in HeLa cells by lentiviral vector. Stable cells and 
parental cells were harvested for western blot analysis. (B) HeLa F-UTX 
cells showed weaker tumorigenic potential. Utilizing the cells as 
described in Figure 4-4 A, soft agar assays were conducted testing the 
anchorage-independent colony formation ability of these cells. Average 
Average colony numbers of triplicates are presented in bar chart. Data 
is depicted as the mean + SD. N=3. 
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A 
B 
C 
Figure 4-5 Utx knockdown leads to increased anchorage-independent cell 
growth activity of MEF cells, which can be rescued by UTX 
complementation. (A) UTX protein levels in Utx knockdown cells as well as 
UTX rescue cells were examined by western blot analysis. Control and two 
kinds of shRNA including sh-Utx1 and sh-Utx4 lentiviruses were infected 
into the MEF cells. Additionally, exogenous UTX was stably expressed in 
the control and Utx knockdown cells by a lentiviral vector. These stable 
cells were harvested for western blot analysis. (B) (C) 
anchorage-independent growth activity in MEF cells was enhanced by Utx 
knockdown and reversed by UTX complementation, indicating the 
potential tumor suppression activity by UTX. The cells described in Figure 
4-5 A were analyzed by soft agar assays (B) and spheroid formation assays 
(C) and average colony numbers of triplicates are presented in the bar 
chart. Data is depicted as the mean + SD. N=3. 
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4.1.4 Molecular mechanisms of this potential UTX tumor suppressor 
function 
• UTX physically interacts with ASH2. 
To further elucidate the molecular mechanism underlying the potential tumor 
suppressor functions of UTX, UTX protein complexes were investigated by 
mass spectrometry analysis.  
 
Figure 4-6 UTX physically interacts with ASH2. MLL2 
and ASH2 proteins were identified in the UTX 
complex. HeLa and HCT116 cells stably expressing 
Flag-tagged UTX were harvested for 
immunoprecipitation with M2 beads and the eluates 
were subjected to a second step of 
immunoprecipitation using UTX antibody. The final 
eluates were analyzed by silver staining. Specific 
bands (labeled with asterisks) were excised for mass 
spectrometry analysis. The interaction between 
ASH2 and UTX was validated by western blot 
analysis.  
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The mass spectrometry results revealed that MLL2 and ASH2 are present in 
the UTX complex, and the interaction between ASH2 and UTX was further 
validated in immunoprecipitation experiments (Figure 4-6). ASH2 has been 
shown as an important component of the H3K4 methyltransferase complexes 
MLL1-4 and SET1A/B, and ASH2 disruption leads to decreased H3K4 
methylation levels as well as reduce gene expression (Steward, Lee et al. 
2006). Since both MLL2 and ASH2 are important components in H3K4 
methyltransferase complex regulating gene transcriptional activation (Shi 
2007), our finding indicates a possible interplay between UTX, MLL2 and 
ASH2 in activating gene transcription, which remains to be further elucidated. 
 
 
• The interaction between ASH2 and UTX is important for the function of 
UTX to repress the anchorage-independent cell growth ability. However, 
the UTX catalytic activity may not be crucial for this function. 
As reviewed above, UTX contains two major functional domains: the TPR 
domain which is important for protein-protein interaction, and the JmjC 
domain which is the catalytic domain enabling its H3K27 demethylase activity 
(Pedersen and Helin 2010). To assess which domain is crucial for UTX to 
function as a potential tumor suppressor, three Flag-tagged UTX mutants 
including HQEtoAQA (catalytically-inactive), del80-397 (TPR-deleted) and 
Y375C (patient mutation) (Figure 4-7 A) were transiently transfected into 
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293T cells or stably expressed in HeLa cells and used for immunoprecipitation 
and soft agar assays respectively. 
 
Figure 4-7 Interaction between ASH2 and UTX is important for UTX’s 
potential tumor suppressing ability in repressing the 
anchorage-independent cell growth. However, UTX catalytic activity may 
not be crucial. (A) Schematic representation presenting the UTX mutants 
HQEtoAQA (catalytically inactive), del80-397 (TPR-deleted) and Y375C 
(patient mutation). (B) The TPR-deleted UTX mutant lost its ability to bind 
ASH2, a component of the MLL2 complex. Flag-tagged UTX mutants 
described in Figure 4-7 A, WT or control plasmid, were transiently 
transfected into 293T cells and subjected for immunoprecipitation by M2 
beads, and analyzed by western blot analysis. (C) UTX mutant or WT or 
control proteins were stably expressed in HeLa cells by lentiviral vector. (D) 
Cells described in Figure 4-7 C were utilized for soft agar assays. Average 
colony numbers of triplicates are presented in the bar chart. Data is 
depicted as the mean + SD. N=3. 
 
 
A B 
C D 
104 
 
Firstly, the immunoprecipitation results showed that the binding region 
between ASH2 and UTX was mapped to the TPR domain of UTX. The UTX 
mutant del80-375 completely lost the ability to bind the ASH2 protein as 
shown in Figure 4-7 B. Secondly, soft agar results revealed the 
anchorage-independent cell growth activity of each mutant. Both WT UTX 
and the JmjC-disrupted mutant HQEtoAQA had potential tumor suppressor 
activities, showing much less colony numbers compared to control. 
Interestingly, the TPR deleted mutant del80-375 gained 
anchorage-independent cell growth activity, showing significantly increased 
colony numbers compared to control (Figure 4-7 D). This indicates that the 
catalytic activity may not be crucial for UTX to repress this 
anchorage-independent cell growth ability; however the interaction between 
ASH2 and UTX is important for its potential tumor suppressing activity, at 
least under the present in vitro experimental conditions. HeLa cells expressing 
the disease-related mutant Y375C lost this potential tumor suppressor 
activity by showing increased colony numbers (Figure 4-7 D, right bottom 
panel), but this mutant still retained the ability to interact with AHS2 in 293T 
cells (Figure 4-7 B, lane 5). Further studies will be necessary to clarify this 
apparent discrepancy. One possibility is that the Y375C-ASH2 interaction may 
be weaker between endogenous proteins with lower expression levels, 
although the interaction was obviously detected following transient 
over-expression system in 293T cells. It is also possible that Y375C loses 
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interaction with other MLL2 complex components besides ASH2 and thus 
leads to increased oncogenic ability, a scenario that remains to be studied. 
 
Summary 
In summary, the function of UTX as a potential tumor suppressor cooperating 
with pVHL or functioning independently in preventing 
anchorage-independent cell growth activity was assessed, and the molecular 
mechanism underlying this effect was also investigated. Further discussion of 
these results will be found in the next section. 
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4.2 Discussion 
 
4.2.1 Important findings and discussion 
This study indicates the potential tumor suppressor functions of UTX, and 
suggests a possible combinational effect of UTX-pVHL in preventing 
tumorigenesis. 
 
• UTX-VHL loss-of-function leads to increased anchorage-independent 
cell growth ability 
In this study, evidence was provided to show the effect of UTX-VHL 
loss-of-function on inducing anchorage-independent cell growth ability, 
which would be an indication of tumorigenic potential. By mimicking the 
effect of UTX-VHL co-mutations, we showed that Vhl-KO+Utx-KD MEF cells 
have increased anchorage-independent cell growth activity, and UTX 
knockdown in pVHL-deficient ccRCC cells leads to a similarly enhanced 
activity. This data provide some preliminary evidence that UTX-VHL 
co-mutations could be one possible cause to induce tumorigenesis in 
ccRCC, which remains to be thoroughly investigated in the future.  
 
Although VHL mutation occurence in ccRCC is as high as up to 50 % - 70 %, 
VHL conditional knockout mouse models indicate that pVHL 
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loss-of-function alone is not sufficient to trigger ccRCC (Haase, Glickman 
et al. 2001), thus additional genetic changes are definitely needed to 
cooperate with VHL mutation and drive full malignant transformation. In 
this sense, a recent report set up a good example by showing that 
combinational mutations of Vhl and p53 could cause renal cysts and 
tumors in mouse, indicating a combinational effect of multiple mutations 
in inducing tumorigenesis (Albers, Rajski et al. 2013). They claimed that at 
5 months old, the Vhl and p53 double knockout mice generated small 
renal cysts (precursors of ccRCC)  and these lesions finally developed into 
tumors at 11 months old. On the contrary, no renal cysts or tumors were 
observed in either the single mutant or control mice. According to a 
sequencing study by BGI, TP53 is found mutated in 7 % (6/81) of human 
ccRCC and co-mutated with VHL in 2 cases (Guo, Gui et al. 2012). This 
TP53 mutation and co-mutations between VHL and TP53 is low in ccRCC, 
but this combination does possess tumor promoting functions as 
validated through the mouse model. In this way, we are encouraged to 
further investigate the potential combinational effect of VHL-UTX 
co-mutations in tumorigenesis in the future. 
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• Molecular mechanisms of the combinational effect of UTX-VHL 
loss-of-function 
Microarray and gene ontology analysis results showed that several 
cancer-related pathways are dysregulated in Vhl-KO+Utx-KD MEF cells. For 
instance, expression of the mTOR activators, RagB and RagD, were 
up-regulated by UTX knockdown. Intriguingly, mTOR pathway is 
commonly activated in ccRCC (Banumathy and Cairns 2010) and mTOR 
inhibitors such as Temsirolimus and Everrolimus (Pal and Quinn 2013) 
have been recently used in ccRCC therapy, although the mechanisms of 
mTOR pathway activation in ccRCC remain unknown. In this case, UTX 
loss-of-function might have a contribution to this mTOR pathway 
activation in ccRCC and be helpful to explain these mechanisms. Moreover, 
we also identified other targets of interest including FOXQ which is known 
to be responsible for anchorage-independent cell growth activity and cell 
proliferation (Kaneda, Arao et al. 2010). These target genes may provide 
an explanation for the gained anchorage-independent cell growth activity 
in Vhl-KO+Utx-KD MEF cells.  
 
• Potential tumor suppressor function of UTX  
Besides ccRCC, UTX mutations have been identified in many other cancer 
types, including bladder cancer, leukemia, prostate cancer, 
medulloblastoma, myeloma and esophageal squamous cell carcinoma 
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(van Haaften, Dalgliesh et al. 2009; Dalgliesh, Furge et al. 2010; Chapman, 
Lawrence et al. 2011; Gui, Guo et al. 2011; Grasso, Wu et al. 2012; Jones, 
Jager et al. 2012; Mar, Bullinger et al. 2012; Kandoth, McLellan et al. 2013; 
Ross, Wang et al. 2014). Furthermore, as reported by Gui, UTX mutation 
events correlate with early grades of bladder cancer (Gui, Guo et al. 2011), 
implying that UTX mutation could be a general driver for tumorigenesis 
across different types of solid tumors. Based on these reports, UTX can 
function as a tumor suppressor in cancer cells that do not have any VHL 
mutation. It was shown in our study that exogenous UTX protein 
expression in HeLa cells resulted in reduced anchorage-independent cell 
growth ability, and Utx knockdown led to increased 
anchorage-independent cell growth ability of MEF cells which can be 
rescued by UTX complementation. In this way, we provide more evidence 
that UTX might be a potential tumor suppressor in human cancer cells. So 
far there are quite limited studies reporting the tumor suppressor role of 
UTX. For instance, re-introduction of WT UTX into UTX mutated 
esophageal cancer cell lines (KYSE-180 and KYSE-450) leads to increased 
cell doubling time and retarded cell proliferation (van Haaften, Dalgliesh 
et al. 2009). Moreover, Utx mutation was also identified from a mouse 
model used to screen for the pancreatic cancer driver mutations. In a 
Sleeping Beauty mutagenesis mouse model driven by Kras, approximately 
five hundred candidate driver mutations were identified and 10 % of 
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these identified genes were chromatin regulators, including Utx (Mann, 
Ward et al. 2012). A recent study demonstrated the tumor suppressor 
function of UTX in T-cell ALL, using both in vitro and in vivo models, 
showing that Utx knockdown can provide murine leukemia cells (MOHITO 
T-ALL mouse cell line) with oncogenic advantage and loss of Utx can lead 
to accelerated leukemia onset in a Notch1-mediated T-ALL mouse model 
(Van der Meulen, Sanghvi et al. 2015). These reports together with our 
findings provide evidence for the potential tumor suppressor function of 
UTX.  
 
• Molecular mechanisms of this potential tumor suppressor function of 
UTX 
Given the observed tumor suppressor functions of UTX, the underlying 
molecular mechanisms were investigated. Protein complex analysis 
revealed that MLL2 and ASH2 interact with UTX, indicating the possible 
interplay between UTX, MLL2 and ASH2 in activating gene transcription. 
UTX and ASH2 were previously detected from purified MLL2 protein 
complexes in leukemia cells (K562) (Issaeva, Zonis et al. 2007). This is in 
agreement with our findings and supports our hypothesis about the 
interplay between these three molecules. Furthermore, through soft agar 
assays we show that the interaction between ASH2 and UTX was 
important for its anchorage-independent cell growth activity, whereas 
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UTX demethylase catalytic activity was not crucial, at least not in our 
experimental system. Remarkably, the catalytic activity of UTX was shown 
to be not critical in development events. Magnuson and colleagues have 
generated knockout mouse models and proved that although Utx and 
Jmjd3 are essential for early embryonic development (Shpargel, Sengoku 
et al. 2012), the catalytic activity of neither Utx nor Jmjd3 is crucial. By 
meta-analysis of categorized gene subsets, the H3K27me3 status of these 
genes shows almost no difference in cells obtained from Utx and Jmjd3 
double knockout mouse embryos compared to those from controls 
(Shpargel, Starmer et al. 2014). Several recent papers also come to the 
similar conclusion that UTX regulates mouse ES cell differentiation and C. 
elegans development independently of its H3K27 demethylase activity 
(Vandamme, Lettier et al. 2012; Wang, Lee et al. 2012). Furthermore, UTY, 
which is the homolog of UTX on the Y chromosome, is able to partially 
compensate for the function of UTX in early embryonic development 
events. Hemizygous XUtx-Y+ mutant male embryos can develop to term, 
and 25 % can survive to adulthood, while homozygous XUtx-XUtx- female 
embryos can only develop until day E12.5. Interestingly, although the UTY 
protein has a conserved JmjC domain and 88 % sequence similarity with 
UTX, it lacks H3K27 demethylase activity. In fact, ectopic UTY cannot 
demethylate H3K27me3 in HEK293T cells (Shpargel, Sengoku et al. 2012). 
Taken together, UTX has a catalytic activity-independent function 
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regulating early embryonic development. Regarding tumorigenesis, there 
are good examples showing that histone modifiers can function 
independently from their catalytic activities. For example, exogenous 
EZH2 mutant deficient for H3K27 methyltransferase activity (SET domain 
deleted mutant) still has the oncogenic ability to confer growth advantage 
in natural killer/T-cell lymphoma cells (NKYS and KHYG) (Yan, Ng et al. 
2013). Whether UTX exhibits its tumor suppresser function independently 
of its catalytic activity still remains unclear. Our findings in the present 
study provide a clue that the interaction between UTX and the H3K4 
methyltransferase MLL2 complex can be important for the potential 
tumor suppressing activity, whereas the UTX demethylase activity might 
Figure 4-8 Diagram showing the 
possible interplay between UTX 
and ASH2 in gene transcription 
activation. UTX and ASH2 are 
present in the same protein 
complex, implying that UTX might 
rely on the methyltransferase 
function of MLL2-ASH2 complex to 
mediate gene transcriptional 
activation. 
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not be crucial in this case. 
 
4.2.2 Limitations of the current study and suggestions for the future 
work 
Currently, conclusive evidence to prove the tumor suppressor function of UTX 
is still missing in our and other investigators’ results. Although off-targeting in 
the Utx knockdown experiments could be theoretically excluded by 
complementing with exogenous UTX expression in our experimental system, 
further studies using e.g. the CRISPR/Cas9 knockout method or utilizing Utx 
knockout mouse cells could provide more robust results to prove the function 
of UTX as a tumor suppressor. Mouse xenograft experiments will definitely be 
necessary to further confirm the tumor suppressor functions of UTX. 
 
Regarding the molecular mechanisms of UTX as a tumor suppressor, 
experiments utilizing point mutations that can severely inhibit interaction 
between UTX and the MLL2 complexes would be very helpful to understand 
the importance of this interaction. Analysis of binding sites on genomic DNA 
by employing chromatin Immunoprecipitation (ChIP) analysis may provide 
information on how and on what genes are targeted by UTX and MLL2, either 
independently or cooperatively, to regulate gene transcription. 
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In addition, further functional consequences and clinical significance of 
cancer-related UTX mutations should be studied in the future. A potential 
application regarding the UTX mutation status is using it as a prognosis marker. 
Small compounds that inhibit UTX-regulated pathways such as mTOR 
pathways may be also useful for therapeutic purposes in cancer patients 
having UTX mutation. 
 
Summary 
In summary, we provide evidence that UTX and pVHL may exhibit a 
combinational effect on suppression of anchorage-independent cell growth 
ability which is indicating tumorigenic potential, and we have indicated 
possible molecular mechanisms which might be related to regulation of 
mTOR pathway and interaction with the MLL2 protein complex. CRISPR/Cas9 
knockout and mouse xenograft studies as well as ChIP analysis are possible 
considerations for future work. Overall, this study provides knowledge for a 
deeper understanding of tumor suppressor role of UTX in ccRCC. 
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Chapter 5 Conclusion 
The biology of cancer development is diverse, complex and remains only 
partially understood. In this study, the physiological function of the tumor 
suppressor pVHL was investigated by two lines of research. In the first part of 
this project, we identified pVHL-FASN interaction and showed regulation of 
HIF-α protein levels via this interaction. FASN upstream regulators such as 
sterols also showed an effect on HIF-1α. A positive correlation of expression 
levels between FASN and HIF-α target genes was observed in patient 
specimen of human prostate cancer, indicating clinical significance. Since the 
pathogenesis of cancers with FASN up-regulation is largely unknown, it can be 
speculated based on our findings that HIF-α and downstream pathways may 
play an important role in these cancers with FASN up-regulation. Moreover, 
the sterol effect on HIF-α may provide a potential strategy to suppress HIF-α 
and downstream pathways, which might be therapeutic avenue in various 
cancers showing up-regulation of HIF-α. In the second part of this project, we 
have investigated the potential tumor suppressor function of UTX, and 
obtained evidence for cooperation between pVHL and UTX in repressing the 
anchorage-independent cell growth ability. We also show that interaction of 
UTX with ASH2 might be essential for the potential tumor suppressing activity 
of UTX. Also, signaling pathways including mTOR pathway, which is a 
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well-known therapeutic target in ccRCC, were shown to be activate by UTX 
down-regulation. In this way, UTX loss of function may partially contribute to 
the dysregulation of mTOR pathway in ccRCC. Taken together, this study 
provides more knowledge of unknown molecular bases and mechanisms 
underlying tumorigenesis, and may provide valuable information contributing 
to targeted drug design and improved cancer therapy. 
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